Compounds > guaifenesin
Page last updated: 2024-10-28

guaifenesin and Airflow Obstruction, Chronic

guaifenesin has been researched along with Airflow Obstruction, Chronic in 224 studies

Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.

Research Excerpts

ExcerptRelevanceReference
"To observe the role of aminophylline and simvastatin in preventing and curing chronic obstructive pulmonary disease (COPD), and to explore the underlying mechanisms based on airway inflammation and mucus hypersecretion."7.83[Effect of aminophylline and simvastatin on airway inflammation and mucus hypersecretion in rats with chronic obstructive pulmonary disease]. ( Deng, X; Li, C; Ren, W; Wang, S; Xiong, L; Zhou, Q; Zhu, C, 2016)
"To explore the preventive and therapeutic effects of simvastatin on rats with chronic obstructive pulmonary disease (COPD) and examine the mechanism of airway inflammation and airway mucus hypersecretion."7.81[Effects of simvastatin on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease]. ( Deng, X; Li, C; Ren, W; Wang, S; Xiong, L; Zhou, Q; Zhu, C, 2015)
"The incidence of chronic obstructive pulmonary disease (COPD) has substantially increased in recent decade."5.42Melatonin attenuates neutrophil inflammation and mucus secretion in cigarette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling. ( Ahn, KS; Hong, JM; Jeon, CM; Kim, JC; Kim, JS; Kwon, OK; Lee, IC; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2015)
"To observe the role of aminophylline and simvastatin in preventing and curing chronic obstructive pulmonary disease (COPD), and to explore the underlying mechanisms based on airway inflammation and mucus hypersecretion."3.83[Effect of aminophylline and simvastatin on airway inflammation and mucus hypersecretion in rats with chronic obstructive pulmonary disease]. ( Deng, X; Li, C; Ren, W; Wang, S; Xiong, L; Zhou, Q; Zhu, C, 2016)
"To explore the preventive and therapeutic effects of simvastatin on rats with chronic obstructive pulmonary disease (COPD) and examine the mechanism of airway inflammation and airway mucus hypersecretion."3.81[Effects of simvastatin on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease]. ( Deng, X; Li, C; Ren, W; Wang, S; Xiong, L; Zhou, Q; Zhu, C, 2015)
") inhibited the number of coughs induced by capsaicin aerosol (P<0."3.74Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. ( Kuraya, T; Morimoto, K; Nosaka, E; Takahashi, S; Tsuchida, H; Yamashita, M, 2008)
"Most patients diagnosed with chronic obstructive pulmonary disease (COPD) present with hallmark features of airway mucus hypersecretion, including cough and expectoration."3.01Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment. ( Shah, BK; Singh, B; Wang, C; Wang, Y; Xie, S, 2023)
"Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide."3.01Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. ( Fang, Q; Gao, X; Yan, Z; Yu, S; Zhang, C, 2021)
"George Respiratory Questionnaire-COPD, SGRQ-C)."2.94CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. ( Ambery, C; Donald, AC; Keeley, T; Lazaar, AL; Miller, BE; Russell, J; Tal-Singer, R; Watz, H, 2020)
"Obstructive lung diseases, such as chronic obstructive pulmonary disease, asthma, or non-cystic fibrosis bronchiectasis, share some major pathophysiological features: small airway involvement, dysregulation of adaptive and innate pulmonary immune homeostasis, mucus hyperproduction, and/or hyperconcentration."2.82Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine! ( Bourdin, A; Charriot, J; Petit, A; Vachier, I; Volpato, M, 2022)
"Among these, COPD is more prominent worldwide."2.82Nanocarrier-based approaches to combat chronic obstructive pulmonary disease. ( Kumar, G; Pathak, K; Sharma, A; Virmani, R; Virmani, T, 2022)
"History of respiratory infections were not associated with an increased prevalence of EFL."2.78[Chronic cough in the elderly is associated with expiratory flow limitation]. ( Barthélémy, JC; Costes, F; Frappé, E; Gautier-Guillot, M; Maudoux, D; Roche, F, 2013)
"Ninety-eight patients with chronic obstructive pulmonary disease and/or chronic bronchitis (n=78), or bronchiectasis (n=20), with a peak cough expiratory flow >150 l/min and sputum production >30 ml/day, randomly included into two treatment groups."2.78Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO® project: a multicentre randomized controlled trial. ( Ambrosino, N; Balbi, B; Berrighi, D; Bianchi, L; Cavicchioli, PP; Clini, EM; Crisafulli, E; Dabrosca, F; DeBiase, A; Galimberti, V; Iattoni, A; Paneroni, M; Righi, D; Schiavoni, G; Vagheggini, G; Venturelli, E; Vitacca, M; Zaurino, M, 2013)
"One hundred and fifty cases of COPD at stable stage, which were in accordance with the inclusive standard were randomly divided into three groups, named group A (treatment in dog days and the three nine-day periods after the winter solstice), group B (treatment in dog days) and group C (treatment in the three nine-day periods after the winter solstice), 50 cases in each group."2.77[Observation of the therapeutic effect on COPD of cold phlegm blocking the lung type at stable stage treated with acupoint sticking therapy in different season]. ( Cao, Y; Huang, XH; Li, JX; Li, W; Li, XP; Liu, XP; Lou, BD; Shi, WY; Yang, LB; Yang, SQ; Zhang, W, 2012)
"Chronic obstructive pulmonary disease (COPD) patients with mucus hypersecretion tend to demonstrate increased frequency of infective exacerbations and a steeper slope of decline in lung function."2.76A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion. ( Austin, G; Chahal, K; Chakravorty, I, 2011)
"Ninety AECOPD patients were randomly divided into Tanreqing group, ambroxol hydrochloride group and control group."2.73[A study of the mechanism of Qingre Huatan therapy in treatment of acute exacerbation of chronic obstructive pulmonary disease by improving airway inflammation and mucus hypersecretion]. ( Chang, J; Guo, J; Li, W; Mao, B; Wan, MH; Wang, G; Wang, L; Zhang, Y, 2008)
"Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and mortality globally."2.66The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease. ( Li, J; Ye, Z, 2020)
"Asthma, chronic obstructive pulmonary disease, and cystic fibrosis are three chronic pulmonary diseases that affect an estimated 420 million individuals across the globe."2.58Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases. ( Breitzig, MT; Kolliputi, N; Lockey, RF; Saco, TV, 2018)
"In asthma and chronic obstructive pulmonary disease (COPD), airway mucus hypersecretion contributes to impaired mucociliary clearance, mucostasis and, potentially, the development of mucus plugging of the airways."2.53Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases. ( Ha, EV; Rogers, DF, 2016)
"Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) have traditionally been viewed as two distinct entities of unrelated origins."2.53Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. ( Cantin, AM, 2016)
"The hallmark traits of chronic obstructive airway diseases are inflammation, airway constriction due to hyperreactivity and mucus overproduction."2.52CLCA1 and TMEM16A: the link towards a potential cure for airway diseases. ( Brett, TJ, 2015)
"CMH frequently occurs in chronic obstructive pulmonary disease (COPD)."2.52Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD. ( Bakke, P; Barr, RG; Beaty, TH; Boezen, HM; Bossé, Y; Brandsma, CA; Burkart, KM; Cho, MH; Crapo, JD; de Koning, HJ; Dijkstra, AE; Groen, HJ; Gulsvik, A; Hiemstra, PS; Lammers, JW; Lomas, DA; Manichaikul, A; Nickle, DC; Paré, PD; Postma, DS; Pottinger, TD; Silverman, EK; Smolonska, J; van den Berge, M; Vonk, JM; Wijmenga, C; Zanen, P, 2015)
"Mucus accumulation in COPD patients affects several important outcomes such as lung function, health-related quality of life, COPD exacerbations, hospitalizations, and mortality."2.50Clinical issues of mucus accumulation in COPD. ( Kim, V; Krahnke, JS; Ramos, FL, 2014)
"The term phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes"."2.48Clinical phenotypes of COPD: identification, definition and implications for guidelines. ( Calle, M; Miravitlles, M; Soler-Cataluña, JJ, 2012)
"COPD is a worldwide public health problem that reduces the quality of life."2.48Pathobiologic mechanisms of chronic obstructive pulmonary disease. ( Sin, DD; Tam, A, 2012)
"The number of senile patients with chronic obstructive pulmonary disease (COPD) has recently increased due to an increase in life expectancy, the habit of smoking and the inhalation of toxic particles."2.48Macrolide effects on the prevention of COPD exacerbations. ( Azuma, A; Kadota, J; Kudoh, S; Takizawa, H; Tamaoki, J; Yamaya, M, 2012)
"To develop an efficient therapy for chronic obstructive pulmonary disease (COPD), N-acetylcysteine (NAC) has been tested as a medication that can suppress various pathogenic processes in this disease."2.48N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. ( Sadowska, AM, 2012)
"Chronic obstructive pulmonary disease (COPD) is characterized by poorly reversible airflow limitation associated with airway remodelling and inflammation of both large and small airways."2.47[Structural abnormalities and inflammation in COPD: a focus on small airways]. ( Bourdin, A; Burgel, PR; Chanez, P; Garcia, G; Pilette, C; Tillie-Leblond, I, 2011)
"Chronic obstructive pulmonary disease (COPD) is a heterogeneous and complex disease of which the basic pathophysiological mechanisms remain largely unknown."2.46Revisited role for mucus hypersecretion in the pathogenesis of COPD. ( Brusasco, V; Cerveri, I, 2010)
"Roflumilast evidently has several pharmacological effects: antiinflammatory, anti-emphysema, and antibiotic actions."2.46[Pharmacological profile of roflumilast]. ( Cortijo Gimeno, J; Morcillo Sánchez, E, 2010)
"The development of COPD is associated with chronic pulmonary inflammation."2.46[COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms]. ( Aguilaniu, B; Aubier, M; Berger, P; Brillet, PY; Burgel, PR; Chambellan, A; Chanez, P; Chaouat, A; Devillier, P; Escamilla, R; Louis, R; Mal, H; Marthan, R; Muir, JF; Pérez, T; Roche, N; Similowski, T; Wallaert, B, 2010)
"The epidemiology of chronic obstructive pulmonary disease (COPD) has been dominated by one hypothesis stating that cigarette smoking and chronic bronchitis were the key to pathogenesis and another that asthma, chronic bronchitis, and even emphysema are related to different expressions of a primary airway abnormality."2.43Convergence of the epidemiology and pathology of COPD. ( Hogg, JC; Vestbo, J, 2006)
"Chronic obstructive pulmonary disease (COPD) is characterized and defined by limitation of expiratory airflow."2.43Pathogenesis of COPD. ( Rennard, SI; Spurzem, JR, 2005)
"Characteristic pathologic changes in chronic obstructive pulmonary disease (COPD) include an increased fractional volume of bronchiolar epithelial cells, fibrous thickening of the airway wall, and luminal inflammatory mucus exudates, which are positively correlated with airflow limitation and disease severity."2.43Airway epithelial stem cells and the pathophysiology of chronic obstructive pulmonary disease. ( Randell, SH, 2006)
"Chronic obstructive pulmonary disease (COPD) is a disease state characterised by airflow obstruction that is not fully reversible and progressive."2.42[Pathophysiology of chronic obstructive pulmonary disease]. ( Maestrelli, P, 2003)
"In the treatment of COPD, long-acting beta(2)-adrenoceptor agonists (LABAs) given twice daily cause the same degree of bronchodilation as tiotropium bromide given once daily."2.42Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? ( Barnes, PJ; Erin, EM; Hansel, TT; Tennant, RC, 2003)
"Acute respiratory infections (ARI) are extremely common at all ages, mostly mild self-limiting illnesses at a young age, but severe often fatal illnesses in elderly people already affected by a chronic disease such as COPD."2.42Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity. ( Lange, P; Miller, DL; Pistelli, R, 2003)
"In severe COPD this may explain the increased mortality associated with the presence of mucus."2.41Epidemiological studies in mucus hypersecretion. ( Vestbo, J, 2002)
"Airway inflammation was also reduced in the Ac-DEVD group compared with the Smoke group, but the degree of emphysema was not significantly improved."1.91Effects of Z-VaD-Ala-Asp-Fluoromethyl Ketone (Z-VAD-FMK) and Acetyl-Asp-Glu-Val-Asp-Aldehyde(Ac-DEVD-CHO) on Inflammation and Mucus Secretion in Mice Exposed to Cigarette Smoke. ( He, M; Li, X; Shen, F; Zhang, G, 2023)
"Among the 4483 participants with COPD, 4363 were included in the primary analysis (median age, 63 years [IQR, 57-70 years]; 44% were women)."1.91Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease. ( Abozeed, M; Ahmed, AN; Aziz, MU; Cho, M; Diaz, AA; Dolliver, WR; Grumley, S; Han, MK; Jacobs, K; Kim, V; Kligerman, SJ; Make, BJ; Manapragada, PP; Nath, HP; Orejas, JL; San José Estépar, R; Sonavane, S; Terry, NL; Wang, W; Washko, GR; Yen, A; Zahid, M, 2023)
"Chronic obstructive pulmonary disease (COPD) is one of the chronic diseases with high morbidity and mortality in China, which imposes heavy economic burden on society."1.91[Advances in molecular mechanism and treatment of chronic mucus hypersecretion]. ( Chen, DH; Dong, YC; Han, YP; Yue, XT; Zhang, JX; Zhu, GL; Zou, XY, 2023)
"Thus, COPD sputum from outpatient clinic, respiratory secretions aspirated from high (HI) and low (LO) airways of COPD patients in acute respiratory insufficiency, and porcine gastric mucus (PGM) were investigated for their permeability to mSLN particles under a magnetic field."1.72Mucopenetration study of solid lipid nanoparticles containing magneto sensitive iron oxide. ( Castellani, S; Cinnella, G; Conese, M; Corbo, F; Cotoia, A; De Giglio, E; Di Gioia, S; Elisiana Carpagnano, G; Larobina, D; Laselva, O; Pia Foschino Barbaro, M; Trapani, A, 2022)
"BACKGROUND Chronic obstructive pulmonary disease (COPD) is a disease with high heterogeneity, which is a major challenge in clinical individualized treatment."1.62Identification of Mucus-Associated Molecular Subtypes of Chronic Obstructive Pulmonary Disease: A Latent Profile Analysis Based on MUC5B-Associated Genes. ( Chen, X; Cheng, X; Hu, Y; Qiu, Z, 2021)
"Based on a COPD rat model, the effects of OECC-BYF I-A~F on COPD rats were evaluated."1.56Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling. ( Dong, H; Feng, S; Li, J; Liu, S; Liu, X; Ma, J; Tian, Y; Wu, M; Zhang, L; Zhao, D; Zhao, P; Zheng, W; Zhu, L, 2020)
"We explored whether the COPD Assessment Test (CAT), a simple measure developed for routine clinical use, captures CMH populations and outcomes similarly to MRC and St."1.56Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort. ( Anderson, W; Comellas, AP; Cooper, CB; Dransfield, M; Drummond, MB; El Baou, C; Han, M; Hansel, NN; Kanner, RE; Keeley, T; Kim, V; Lazaar, AL; Martinez, FJ; Miller, B; Müllerová, H; Ortega, VE; Paine Iii, R; Stott-Miller, M; Tabberer, M; Tal-Singer, R; Woodruff, P, 2020)
"Chronic obstructive pulmonary disease (COPD) is an intractable disease involving a sticky mucus layer and nanoagents with mucus-penetrating capability offer a new way to deliver drugs."1.56Mediated Drug Release from Nanovehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease. ( Chu, PK; Geng, S; Hu, WP; Hua, JL; Li, Z; Luo, G; Wang, H; Yu, XF; Zhang, J, 2020)
"Pneumocystis associates to more severe Chronic Obstructive Pulmonary Disease (COPD), asthma, respiratory distress of premature newborns, and is a consistent subclinical infection between 2 and 5 months of age when hospitalizations for respiratory cause and infant mortality are higher."1.51Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection. ( Bórquez, P; Bustamante, R; Gallo, M; Iturra, PA; Méndez, A; Ponce, CA; Rojas, DA; Vargas, SL, 2019)
"Dithiothreitol and P3001 were directly compared with NAC in vitro and both exhibited superior reducing activities."1.51An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. ( Boucher, RC; Delion, MF; Donaldson, SH; Ehre, C; Esther, CR; Fontana, NC; Grubb, BR; Hill, DB; Hothem, LN; Kato, T; Livraghi-Butrico, A; Markovetz, MR; Morrison, CB; Rushton, ZL; Thelin, WR; Villalon, D; Wang, B, 2019)
"Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide."1.51Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment. ( Amore, E; Bondì, ML; Di Vincenzo, S; Ferraro, M; Giammona, G; Gjomarkaj, M; La Parola, V; Manca, ML; Pace, E; Valenti, D, 2019)
"Phloretin pretreatment dramatically suppressed the mucins secretion, inflammatory cell infiltration and inflammatory cytokine release in mouse lungs induced by CS, and it also suppressed CSE-induced expression of MUC5AC and IL-1β in NCI-H292 bronchial epithelial cells."1.48Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke. ( Chen, L; Hao, N; Shen, Y; Wang, H; Wang, T; Wen, F; Wu, Y; Yang, T; Yuan, Z, 2018)
"Mucus plugs are a plausible mechanism of chronic airflow obstruction in severe asthma, and EPO-generated oxidants may mediate mucus plug formation."1.48Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. ( Bleecker, ER; Castro, M; Di Maio, S; Dunican, EM; Elicker, BM; Erzurum, SC; Fahy, JV; Fain, SB; Gierada, DS; Gordon, ED; Hoffman, EA; Israel, E; Jarjour, NN; Lachowicz-Scroggins, ME; Levy, BD; Mauger, DT; Meyers, DA; Nagle, SK; Newell, JD; Peters, MC; Phillips, BR; Raymond, WW; Schiebler, ML; Wenzel, SE; Woodruff, PG, 2018)
"The penetration studies of mucus from COPD patients showed that the PEG-LIPOSOMEs were the most mucus-penetrating vesicles after 27 h."1.48Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. ( Agostiano, A; Castellani, S; Catucci, L; Comparelli, R; Conese, M; De Leo, V; Di Gioia, S; Mandracchia, D; Milano, F; Ruscigno, S; Trapani, A; Trapani, G, 2018)
"Chronic obstructive pulmonary disease (COPD) is a chronic, progressive and lethal lung disease with few treatments."1.48Limax extract ameliorates cigarette smoke-induced chronic obstructive pulmonary disease in mice. ( Guan, R; Li, D; Liang, X; Long, Z; Lu, W; Wang, J; Wang, Z; Xie, J; Xu, J; Yang, Q; Zhao, L, 2018)
"Daily cough was recorded in 28."1.48Mucus hypersecretion in asthma is associated with rhinosinusitis, polyps and exacerbations. ( Crespo, A; García-Rivero, JL; López-Viña, A; Marina-Malanda, N; Martínez-Rivera, C; Mayoralas-Alises, S; Padilla, A; Pallarés-Sanmartín, A; Pascual-Erquicia, S; Picado, C; Pinedo-Sierra, C; Plaza, V, 2018)
"Sprague-Dawley rats were made chronic obstructive pulmonary disease models via tobacco smoke exposure for 12 weeks and the rats were treated with 10 ml/kg hydrogen-rich saline intraperitoneally during the last 4 weeks."1.46Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats. ( Geng, W; Jiang, C; Li, C; Liu, Y; Liu, Z; Qin, S; Si, Y; Zhang, X; Zhang, Y; Zhao, S, 2017)
"The rat COPD model was established using a combination of passive cigarette smoking and intratracheal instillation of lipopolysaccharide (LPS)."1.43Pinellia ternata Attenuates Mucus Secretion and Airway Inflammation after Inhaled Corticosteroid Withdrawal in COPD Rats. ( Du, W; Gong, X; Huang, Q; Su, J; Wang, Y; Ye, D, 2016)
"There are increased proteases in the COPD airway but changes in protease-antiprotease balance and mucin degradation have not been investigated during the course of a COPD exacerbation."1.42Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction. ( Chillappagari, S; Guenther, A; Henke, MO; Licht, S; Mahavadi, P; Müller, C; Nahrlich, L; Preuss, J; Rubin, BK; Sarode, G; Vogelmeier, C, 2015)
"The incidence of chronic obstructive pulmonary disease (COPD) has substantially increased in recent decade."1.42Melatonin attenuates neutrophil inflammation and mucus secretion in cigarette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling. ( Ahn, KS; Hong, JM; Jeon, CM; Kim, JC; Kim, JS; Kwon, OK; Lee, IC; Oh, SR; Park, JW; Shin, IS; Shin, NR, 2015)
"20 prospectively enrolled COPD patients (GOLD I-IV) underwent 1H-MRI of the lung at 1."1.42Morpho-Functional 1H-MRI of the Lung in COPD: Short-Term Test-Retest Reliability. ( Anjorin, A; Biederer, J; Jobst, BJ; Kauczor, HU; Ley, S; Ley-Zaporozhan, J; Sedlaczek, O; Triphan, SM; Wielpütz, MO, 2015)
"(CJT) on the development of COPD using a Cigarette smoke (CS)-induced murine model and cigarette smoke condensate (CSC)-stimulated H292 cells, human pulmonary mucoepidermoid cell line."1.42Callicarpa japonica Thunb. attenuates cigarette smoke-induced neutrophil inflammation and mucus secretion. ( Ahn, KS; Hee Kim, J; Kwon, OK; Lee, HJ; Lee, HS; Lee, J; Lee, JW; Oh, SR; Park, JW; Park, SY; Shin, NR; Zhang, ZY, 2015)
"1479 persons with and 8529 without COPD, participating in the general population-based LifeLines cohort, completed questionnaires and underwent spirometry."1.40Risk factors for chronic mucus hypersecretion in individuals with and without COPD: influence of smoking and job exposure on CMH. ( Boezen, HM; de Jong, K; Dijkstra, AE; Groen, HJ; Kromhout, H; Postma, DS; Vermeulen, R; Vonk, JM, 2014)
"Cough and phlegm are common in COPD."1.40Chronic productive cough is associated with death in smokers with early COPD. ( Connett, JE; Drummond, MB; Hansel, NN; Putcha, N; Scanlon, PD; Tashkin, DP; Wise, RA, 2014)
"Prevalence of night-time dyspnoea in COPD increases with disease severity according to both spirometric and clinical GOLD classification, and is associated with presence of daytime respiratory symptoms and cardiac comorbidities."1.40Prevalence of night-time dyspnoea in COPD and its implications for prognosis. ( Lange, P; Marott, JL; Nordestgaard, BG; Vestbo, J, 2014)
"Progression of chronic obstructive pulmonary disease is associated with small airway obstruction by accumulation of inflammatory mucous exudates."1.40β2-Adrenoceptor involved in smoking-induced airway mucus hypersecretion through β-arrestin-dependent signaling. ( Guo, Y; He, B; Xu, M; Zhang, Y; Zhou, Y, 2014)
"Chronic obstructive pulmonary disease (COPD) involves aberrant airway inflammatory responses to cigarette smoke (CS) that are associated with epithelial cell dysfunction, cilia shortening, and mucociliary clearance disruption."1.39Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction. ( An, CH; Bhashyam, AR; Biswal, SS; Cervo, M; Choi, AM; Chung, AL; Cloonan, SM; Franks, JM; Haley, KJ; Haspel, JA; Kim, HP; Lam, HC; Mahmood, A; Mizumura, K; Owen, CA; Quackenbush, J; Rahman, I; Ryter, SW; Sathirapongsasuti, JF; Shan, B; Silverman, EK; Singh, A; Tesfaigzi, Y; Washko, GR; Yao, H, 2013)
"As recurrent airway obstruction (RAO) is progressive and as medical history is frequently unknown by owners, it's important to suggest a score model to characterize RAO stages for a more accurate diagnosis and treatment."1.38Correlation and discriminant analysis between clinical, endoscopic, thoracic X-ray and bronchoalveolar lavage fluid cytology scores, for staging horses with recurrent airway obstruction (RAO). ( Branco Ferreira, M; Sales Luis, JP; Tilley, P, 2012)
" The current study compared three rat models induced by cigarette smoke (CS) exposure alone or combined with pre- or post-treatment with lipopolysaccharide (LPS)."1.38Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: to establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease. ( Li, PB; Luo, YL; Nie, YC; Shen, JG; Su, WW; Wu, H; Zhang, CC, 2012)
"Chronic obstructive pulmonary disease (COPD) is a chronic progressive inflammatory disease characterized by elevated lung neutrophils, macrophages, and CD8+ T lymphocytes and mucus hypersecretion."1.36Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung. ( Baccei, CS; Bain, G; Broadhead, AR; Coate, H; Evans, JF; Fagan, P; Hutchinson, JH; King, CD; Lorrain, DS; Prasit, P; Prodanovich, P; Santini, AM; Scott, JM; Stearns, BA; Stebbins, KJ; Stock, NS; Truong, YP, 2010)
" Smoking and asthma were risk factors for CMH, with a dose-response effect of tobacco consumption, and smoking habits also predicting incidence of CMH."1.36Chronic mucus hypersecretion: prevalence and risk factors in younger individuals. ( Backer, V; Harmsen, L; Ingebrigtsen, T; Kyvik, KO; Skadhauge, LR; Steffensen, IE; Thomsen, SF, 2010)
"60 patients with COPD and 35 normal subjects were involved in the study."1.36[The relationship between the lung function and the level of TNF-α in serum in COPD department of respiratory]. ( Dao-xin, W; Yong-hong, Y, 2010)
"Chronic obstructive pulmonary disease (COPD) is an inflammatory process characterized by airway mucus hypersecretion."1.35LPS-stimulated MUC5AC production involves Rac1-dependent MMP-9 secretion and activation in NCI-H292 cells. ( Binker, MG; Binker-Cosen, AA; Cosen-Binker, LI; Oliver, B; Richards, D, 2009)
"It is stated that chronic obstructive pulmonary diseases patients observe the significant variation of bronchial clearance's tempos, imbalance in the system of lipids' peroxide oxidation and antioxidant defense during aggravation and remission."1.35[State of the mucociliary system in patients of senior age with chronic obstructive pulmonary diseases]. ( Kozlov, BI; Nagin, AP; Vishniakov, AA, 2008)
"In both asthma and COPD mouse models, pendrin was up-regulated at the apical side of airway epithelial cells in association with mucus overproduction."1.35Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. ( Aizawa, H; Arima, K; Fukuda, T; Green, ED; Hasegawa, M; Hayashi, H; Hoshino, T; Inoue, H; Inoue, M; Izuhara, K; Kanaji, S; Kubo, H; Matsushita, H; Nagai, H; Nakao, I; Nakayama, K; Ohta, S; Okinami, S; Sagara, H; Shiraki, A; Sugiyama, K; Suzuki, K; Tanaka, H; Toda, S; Watanabe, M; Yamaya, M; Yuyama, N, 2008)
"To assess the incidence of COPD in a cohort of young adults and to test whether chronic cough/phlegm and dyspnea are independent predictors of COPD."1.34Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. ( Accordini, S; Ackermann-Liebrich, U; Antó, JM; Burney, P; Cerveri, I; Chinn, S; Corsico, A; de Marco, R; Gislason, T; Heinrich, J; Janson, C; Jarvis, D; Künzli, N; Leynaert, B; Neukirch, F; Schouten, JP; Sunyer, J; Svanes, C; Vermeire, P; Wjst, M, 2007)
"COPD is associated with reduced life expectancy."1.34Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. ( Cherniack, RM; Chu, FS; Coxson, HO; Criner, GJ; Elliott, WM; Hogg, JC; Luketich, JD; Make, BJ; Martinez, FJ; Pare, PD; Patel, SA; Rogers, RM; Sciurba, FC; Sharafkhaneh, A; Sin, DD; Tan, WC, 2007)
"Chronic obstructive pulmonary disease (COPD) is usually complicated with mucus overproduction in airway."1.34Increased expression of human calcium-activated chloride channel 1 is correlated with mucus overproduction in the airways of Chinese patients with chronic obstructive pulmonary disease. ( Chen, XR; Deng, ZP; Feng, YL; Ou, XM; Wang, K; Wen, FQ; Xu, D; Yang, J, 2007)
"Twenty-five patients were diagnosed as COPD patients, and another 20 were diagnosed as the control patients."1.34Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease. ( Chen, XR; Deng, ZP; Feng, YL; Ou, XM; Wang, K; Wen, FQ; Xu, D; Yang, J, 2007)
"We studied 10 steady-state COPD patients, eight patients with community-acquired pneumonia and eight healthy subjects as controls."1.33Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. ( Allegra, L; Ambrosetti, U; Piatti, G; Santus, P, 2005)
"One hundred and two COPD patients and 183 controls, together with 46 asthma patients and 48 patients with chronic mucous hypersecretion (CMH) were examined."1.32Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland. ( Andrason, H; Gislason, T; Gulcher, JR; Hakonarson, H; Halapi, E; Jónasson, K; Laufs, J; Sigvaldason, A; Söebech, E; Stefansson, K; Thorsteinsson, L, 2004)
"Pulmonary and Critical Care Division, COPD Center at St."1.31Cough and phlegm are important predictors of health status in smokers without COPD. ( Celli, BR; Heijdra, YF; Kenney, LA; Pinto-Plata, VM; Rassulo, J, 2002)

Research

Studies (224)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's65 (29.02)29.6817
2010's112 (50.00)24.3611
2020's47 (20.98)2.80

Authors

AuthorsStudies
Dhar, R1
Yong-hong, Y1
Dao-xin, W1
Yu, S1
Zhang, C1
Yan, Z1
Fang, Q1
Gao, X1
Qin, Y1
Li, M2
Tian, Y3
Zhao, P2
Li, K1
Li, C5
Li, J4
Hill, DB3
Button, B1
Rubinstein, M1
Boucher, RC7
Tasena, H2
Timens, W6
van den Berge, M7
van Broekhuizen, J1
Kennedy, BK1
Hylkema, MN2
Brandsma, CA6
Heijink, IH2
Singanayagam, A2
Footitt, J1
Marczynski, M1
Radicioni, G2
Cross, MT1
Finney, LJ2
Trujillo-Torralbo, MB2
Calderazzo, M1
Zhu, J5
Aniscenko, J2
Clarke, TB1
Molyneaux, PL1
Bartlett, NW2
Moffatt, MF2
Cookson, WO2
Wedzicha, J1
Evans, CM4
Kesimer, M2
Lieleg, O1
Mallia, P2
Johnston, SL2
Charriot, J1
Volpato, M1
Petit, A2
Vachier, I2
Bourdin, A3
Wei, YY1
Zhang, DW1
Ye, JJ1
Lan, QX1
Ji, S1
Sun, L2
Li, F2
Fei, GH1
Virmani, T1
Kumar, G1
Virmani, R1
Sharma, A1
Pathak, K1
Castellani, S2
Trapani, A2
Elisiana Carpagnano, G1
Cotoia, A1
Laselva, O1
Pia Foschino Barbaro, M1
Corbo, F1
Cinnella, G1
De Giglio, E1
Larobina, D1
Di Gioia, S2
Conese, M2
Thompson, PJ1
Criner, GJ4
Dransfield, MT1
Halpin, DMG1
Han, MK4
Lipson, DA1
Maghzal, GJ1
Martinez, FJ4
Midwinter, D1
Singh, D3
Tombs, L1
Wise, RA2
Ko, FWS1
Hui, DSC1
Chang, C1
Wu, JW1
Peng, YS1
Liu, KX1
Tran, C1
Singh, GV1
Haider, E1
Boylan, C1
Venegas, C1
Riaz, S1
Al Duwaiki, S1
Yehia, M1
Ho, T1
Nair, P1
Svenningsen, S1
Kirby, M1
Rathnayake, SNH3
Ditz, B3
van Nijnatten, J3
Sadaf, T3
Hansbro, PM3
van Schadewijk, A3
Hiemstra, PS5
Ten Hacken, NHT4
Oliver, B4
Kerstjens, HAM3
Faiz, A4
Pangeni, R1
Meng, T1
Poudel, S1
Sharma, D1
Hutsell, H1
Ma, J3
Rubin, BK6
Longest, W1
Hindle, M1
Xu, Q1
He, M1
Zhang, G1
Shen, F1
Li, X1
Xu, K1
Lu, R1
Shao, X1
Zhao, Y3
Cui, L1
Qiu, Z2
Wu, D1
Xiang, Y1
Wei, L1
Hongping, H1
Chufang, L1
Cuomu, M1
Jintao, L1
Kaiyin, C1
Lvyi, C1
Weiwu, C1
Zuguang, Y1
Nanshan, Z1
Xu, C1
Wang, S6
Diaz, AA3
Orejas, JL1
Grumley, S1
Nath, HP2
Wang, W1
Dolliver, WR2
Yen, A2
Kligerman, SJ1
Jacobs, K2
Manapragada, PP1
Abozeed, M1
Aziz, MU1
Zahid, M1
Ahmed, AN1
Terry, NL1
San José Estépar, R3
Kim, V5
Make, BJ2
Sonavane, S1
Washko, GR3
Cho, M1
Van Buren, E1
Lester, S1
O'Neal, WK3
Dang, H1
Kasela, S1
Garudadri, S1
Curtis, JL2
Krishnan, JA2
Wan, ES1
Silverman, EK4
Hastie, A1
Ortega, VE3
Lappalainen, T1
Nawijn, MC2
Berge, MVD1
Christenson, SA2
Li, Y3
Cho, MH3
Kelada, SNP1
Shah, BK1
Singh, B1
Wang, Y3
Xie, S1
Wang, C1
Kumar, S1
Parveen, S1
Swaroop, S1
Banerjee, M1
Alghamdi, SM1
Alzahrani, A1
Alshahrani, YM1
Al Ruwaithi, AA1
Aldhahir, AM1
Alsulayyim, AS1
Siraj, RA1
Almansour, AH1
Alasmari, AM1
Alqahtani, JS1
Alanazi, AM1
Jaishi, ST1
Allehyani, BA1
Hopkinson, NS1
Hsu, NC1
Lin, HY1
Hsu, CH1
Keeler, SP1
Wu, K1
Zhang, Y8
Mao, D1
Iberg, CA1
Austin, SR1
Glaser, SA1
Yantis, J1
Podgorny, S1
Brody, SL1
Chartock, JR1
Han, Z1
Byers, DE2
Romero, AG2
Holtzman, MJ2
Yue, XT1
Zou, XY1
Zhu, GL1
Chen, DH1
Dong, YC1
Han, YP1
Zhang, JX1
Cabrita, I1
Benedetto, R1
Schreiber, R1
Kunzelmann, K1
Cook, N1
Gey, J1
Oezel, B1
Mackay, AJ1
Kumari, C1
Kaur, VP1
Larkin, N1
Harte, J1
Vergara-Muro, S1
Gutzwiller, FS1
Boudewijn, IM1
Berg, M1
Lin, VY1
Kaza, N1
Birket, SE1
Kim, H1
Edwards, LJ1
LaFontaine, J1
Liu, L1
Mazur, M1
Byzek, SA1
Hanes, J1
Tearney, GJ1
Raju, SV1
Rowe, SM1
Liu, W1
Zhang, X3
Mao, B3
Jiang, H1
Yang, T2
Wang, H3
Zeng, Z1
Shen, Y3
Wan, C1
Wu, Y4
Dong, J1
Chen, L3
Wen, F3
Burgel, PR6
Liu, X1
Dong, H1
Zheng, W1
Feng, S1
Zhang, L1
Wu, M2
Zhu, L1
Liu, S1
Zhao, D1
Lazaar, AL2
Miller, BE1
Donald, AC1
Keeley, T2
Ambery, C1
Russell, J1
Watz, H1
Tal-Singer, R2
Li, Z3
Luo, G1
Hu, WP1
Hua, JL1
Geng, S1
Chu, PK1
Zhang, J3
Yu, XF1
Ye, Z1
Stott-Miller, M1
Müllerová, H1
Miller, B1
Tabberer, M1
El Baou, C1
Han, M1
Dransfield, M2
Hansel, NN3
Cooper, CB2
Woodruff, P1
Comellas, AP1
Paine Iii, R1
Kanner, RE1
Anderson, W2
Drummond, MB3
Dunican, EM2
Elicker, BM2
Henry, T1
Gierada, DS2
Schiebler, ML2
Barjaktarevic, I1
Barr, RG2
Bleecker, ER2
Bowler, R1
Comellas, A1
Couper, D1
Doerschuk, CM1
Hastie, AT1
Hoffman, EA2
Lazarus, SC1
McCulloch, CE1
Paine, R1
Peters, S1
Schroeder, JD1
Woodruff, PG2
Fahy, JV3
Chassagnon, G1
Wan, N1
Tang, X2
Ding, H1
Yan, Y1
Zhuang, Y1
Qi, C1
Chen, Q1
Xie, W2
Liang, M1
Ning, W1
Cao, J2
Minet, E1
Haswell, LE1
Corke, S1
Banerjee, A1
Baxter, A1
Verrastro, I1
De Abreu E Lima, F1
Jaunky, T1
Santopietro, S1
Breheny, D1
Gaça, MD1
Grumley, SA1
Terry, N1
Ahmed, A1
Kligerman, S1
Wan, NS1
Yang, X2
Lai, T1
Jing, D1
Yang, S1
Zhou, L1
Chen, H1
Shen, J1
Li, W4
Ying, S1
Chen, Z1
Wu, X1
Shen, H1
Hu, Y1
Cheng, X1
Chen, X1
Yan, X1
Song, Y1
Shen, C1
Xu, W1
Liu, H1
Huang, M1
Lai, G1
Qian, G1
Wang, J3
Ye, X1
Zheng, J1
Bai, C1
Livraghi-Butrico, A2
Grubb, BR2
Wilkinson, KJ1
Volmer, AS1
Burns, KA1
Carraro, G1
Stripp, BR1
Liu, Z1
Geng, W1
Jiang, C1
Zhao, S1
Liu, Y1
Qin, S1
Si, Y1
Wedzicha, JA2
Saco, TV1
Breitzig, MT1
Lockey, RF1
Kolliputi, N1
Liang, X1
Guan, R1
Zhao, L1
Li, D1
Long, Z1
Yang, Q1
Xu, J1
Wang, Z2
Xie, J1
Lu, W2
Wang, T1
Hao, N1
Yuan, Z1
Nagle, SK1
Newell, JD1
Raymond, WW1
Lachowicz-Scroggins, ME1
Di Maio, S1
Castro, M1
Fain, SB1
Jarjour, NN1
Israel, E1
Levy, BD1
Erzurum, SC1
Wenzel, SE1
Meyers, DA1
Phillips, BR1
Mauger, DT1
Gordon, ED1
Peters, MC1
Khelloufi, MK1
Loiseau, E1
Jaeger, M1
Molinari, N1
Chanez, P4
Gras, D2
Viallat, A1
Martínez-Rivera, C1
Crespo, A1
Pinedo-Sierra, C1
García-Rivero, JL1
Pallarés-Sanmartín, A1
Marina-Malanda, N1
Pascual-Erquicia, S1
Padilla, A1
Mayoralas-Alises, S1
Plaza, V1
López-Viña, A1
Picado, C1
Huang, S1
Kang, J3
Lin, J1
Lai, K1
Sun, Y1
Xiao, W2
Yang, L1
Yao, W1
Cai, S1
Huang, K1
De Leo, V1
Ruscigno, S1
Milano, F1
Mandracchia, D1
Comparelli, R1
Agostiano, A1
Trapani, G1
Catucci, L1
Glanville, N1
Girkin, JL1
Ching, YM1
Marcellini, A1
Porter, JD1
Toussaint, M1
Walton, RP1
Calderazzo, MA1
Grainge, C1
Loo, SL1
Veerati, PC1
Pathinayake, PS1
Nichol, KS1
Reid, AT1
James, PL1
Solari, R1
Wark, PAB1
Knight, DA2
Edwards, MR1
Gao, Z1
Halmurat, U1
Jing, J1
Xu, D5
Atanasova, KR1
Reznikov, LR1
Fernández-Blanco, JA1
Fakih, D1
Arike, L1
Rodríguez-Piñeiro, AM1
Martínez-Abad, B1
Skansebo, E1
Jackson, S1
Root, J1
McCrae, C1
Åstrand, A1
Ermund, A1
Hansson, GC2
Ehre, C2
Rushton, ZL1
Wang, B1
Hothem, LN1
Morrison, CB1
Fontana, NC1
Markovetz, MR1
Delion, MF1
Kato, T1
Villalon, D1
Thelin, WR1
Esther, CR1
Donaldson, SH2
Rojas, DA1
Iturra, PA1
Méndez, A1
Ponce, CA1
Bustamante, R1
Gallo, M1
Bórquez, P1
Vargas, SL1
Higham, A1
Quinn, AM1
Cançado, JED1
Amore, E1
Manca, ML1
Ferraro, M1
Valenti, D1
La Parola, V1
Di Vincenzo, S1
Gjomarkaj, M1
Giammona, G1
Bondì, ML1
Pace, E1
Knabe, L1
Khelloufi, K1
Jory, M1
Cabon, Y1
Begg, M1
Richard, S1
Massiera, G1
Crespo-Lessmann, A1
Torrego-Fernández, A1
Lillehoj, EP1
Kato, K1
Kim, KC1
Marin, L1
Traini, D1
Bebawy, M1
Colombo, P1
Buttini, F1
Haghi, M1
Ong, HX1
Young, P1
Frappé, E1
Gautier-Guillot, M1
Barthélémy, JC1
Maudoux, D1
Roche, F1
Costes, F1
Graeber, SY1
Zhou-Suckow, Z2
Schatterny, J2
Hirtz, S2
Mall, MA3
Putcha, N1
Connett, JE1
Scanlon, PD1
Tashkin, DP1
Li, MC1
Yang, G1
Zhou, XD2
Tselluyko, S1
Perelman, JM2
Lam, HC1
Cloonan, SM1
Bhashyam, AR1
Haspel, JA1
Singh, A1
Sathirapongsasuti, JF1
Cervo, M1
Yao, H1
Chung, AL1
Mizumura, K1
An, CH1
Shan, B1
Franks, JM1
Haley, KJ1
Owen, CA1
Tesfaigzi, Y2
Quackenbush, J1
Rahman, I1
Kim, HP1
Mahmood, A1
Biswal, SS1
Ryter, SW1
Choi, AM1
Jiang, Y1
Sun, C1
Wang, Q1
Yang, Z1
Pan, X1
Zhu, M1
Lange, P3
Marott, JL1
Vestbo, J7
Nordestgaard, BG2
Ramos, FL1
Krahnke, JS1
Vasquez, PA1
Mellnik, J1
McKinley, SA1
Vose, A1
Mu, F1
Henderson, AG1
Alexis, NE1
Forest, MG1
Dijkstra, AE3
de Jong, K1
Boezen, HM3
Kromhout, H1
Vermeulen, R1
Groen, HJ3
Postma, DS3
Vonk, JM3
Smolonska, J2
Wijmenga, C2
Zanen, P2
Luinge, MA1
Platteel, M1
Lammers, JW2
Dahlback, M1
Tosh, K1
Sterk, PJ1
Spira, A1
Benn, M1
Nielsen, SF1
Dahl, M1
Verschuren, WM1
Picavet, HS1
Smit, HA1
Owsijewitsch, M1
Kauczor, HU2
de Koning, HJ2
Nizankowska-Mogilnicka, E1
Mejza, F1
Nastalek, P1
van Diemen, CC1
Crapo, JD2
Beaty, TH2
Lomas, DA2
Bakke, P2
Gulsvik, A2
Bossé, Y2
Obeidat, M1
Obeidat, MA1
Loth, DW1
Lahousse, L1
Rivadeneira, F1
Uitterlinden, AG1
Hofman, A1
Stricker, BH1
Brusselle, GG1
van Duijn, CM1
Brouwer, U1
Koppelman, GH1
Osadnik, CR1
McDonald, CF1
Holland, AE1
Trojanek, JB1
Cobos-Correa, A1
Diemer, S1
Kormann, M1
Schubert, SC1
Agrawal, R1
Duerr, J1
Wagner, CJ1
Sommerburg, O1
Hartl, D1
Schultz, C1
Martin, C2
Frija-Masson, J1
Zhou, Y1
Guo, Y1
Xu, M1
He, B1
Wysocka, B1
Kluciński, W1
Burkart, KM1
Manichaikul, A1
Pottinger, TD1
Nickle, DC1
Paré, PD2
Shin, IS1
Shin, NR2
Park, JW3
Jeon, CM1
Hong, JM1
Kwon, OK4
Kim, JS1
Lee, IC1
Kim, JC1
Oh, SR4
Ahn, KS4
Chillappagari, S1
Preuss, J1
Licht, S1
Müller, C1
Mahavadi, P1
Sarode, G1
Vogelmeier, C1
Guenther, A1
Nahrlich, L1
Henke, MO2
Brett, TJ2
Jobst, BJ1
Wielpütz, MO1
Triphan, SM1
Anjorin, A1
Ley-Zaporozhan, J1
Biederer, J1
Ley, S1
Sedlaczek, O1
Lee, JW3
Park, SY1
Lee, HS1
Hee Kim, J1
Lee, HJ4
Lee, J2
Zhang, ZY1
Baraniuk, JN1
Casado, B1
Pannell, LK1
McGarvey, PB1
Boschetto, P1
Luisetti, M1
Iadarola, P1
Xiong, LL1
Ren, W3
Zhu, CD1
Li, CY1
Zhou, Q3
Tamaoki, J4
Nagai, A1
Ha, EV1
Rogers, DF7
Allinson, JP1
Hardy, R1
Donaldson, GC1
Shaheen, SO1
Kuh, D1
Xiong, L2
Deng, X2
Zhu, C2
Franchini, ML1
Athanazio, R1
Amato-Lourenço, LF1
Carreirão-Neto, W1
Saldiva, PH1
Lorenzi-Filho, G1
Nakagawa, NK1
Cantin, AM1
Behrsing, H1
Raabe, H1
Manuppello, J1
Bombick, B1
Curren, R1
Sullivan, K1
Sethi, S1
Phipps, R1
Yan, S1
D'Ruiz, C1
Tarran, R1
Constant, S1
Phillips, G1
Gaça, M1
Hayden, P1
Cao, X1
Mathis, C1
Hoeng, J1
Braun, A1
Hill, E1
Tagaya, E1
Yagi, O1
Sato, A1
Arimura, K1
Takeyama, K1
Kondo, M2
Paz, C1
Suárez, E1
Vence, J1
Du, W1
Su, J1
Ye, D1
Huang, Q1
Gong, X1
Juan, Y1
Haiqiao, W1
Huaping, H1
Zhong, H1
Xiangdong, Z1
Kolosov, VP1
Park, HA1
Jang, YG1
Kim, JY1
Choi, BK1
Lee, S1
Paik, JH1
Chen, J1
Zhang, W2
Peng, D1
Xia, Y1
Lu, Y1
Han, X1
Song, G1
Liu, R1
Jeong, HG1
Kim, JH1
Eid, R1
Bickel, S1
Eid, N1
Nagin, AP1
Kozlov, BI1
Vishniakov, AA1
Wang, G2
Wang, L2
Chang, J2
Wan, MH2
Guo, J2
Tsuchida, H1
Takahashi, S1
Nosaka, E1
Kuraya, T1
Yamashita, M1
Morimoto, K1
Koo, JS1
Voynow, JA2
Langer, D1
Hendriks, E1
Burtin, C1
Probst, V1
van der Schans, C1
Paterson, W1
Verhoef-de Wijk, M1
Straver, R1
Klaassen, M1
Troosters, T1
Decramer, M2
Ninane, V1
Delguste, P1
Muris, J1
Gosselink, R1
Binker, MG1
Binker-Cosen, AA1
Richards, D1
Cosen-Binker, LI1
Simpson, JL1
Phipps, S1
Gibson, PG1
Mateos-Corral, D1
Cutz, E1
Solomon, M1
Ratjen, F1
Stebbins, KJ1
Broadhead, AR1
Baccei, CS1
Scott, JM1
Truong, YP1
Coate, H1
Stock, NS1
Santini, AM1
Fagan, P1
Prodanovich, P1
Bain, G1
Stearns, BA1
King, CD1
Hutchinson, JH1
Prasit, P1
Evans, JF1
Lorrain, DS1
Gaschler, GJ1
Zavitz, CC1
Bauer, CM1
Stämpfli, MR1
Zheng, YQ1
Harmsen, L1
Thomsen, SF1
Ingebrigtsen, T1
Steffensen, IE1
Skadhauge, LR1
Kyvik, KO1
Backer, V1
Lin, JL1
Thomas, PS1
Lai, H1
Williams, BJ1
Dehnbostel, J1
Blackwell, TS1
Tang, L1
Xu, Y1
Cerveri, I2
Brusasco, V2
Balsamo, R1
Lanata, L1
Egan, CG1
Janssens, W1
Dickey, BF1
Aubier, M1
Marthan, R1
Berger, P1
Chambellan, A1
Aguilaniu, B1
Brillet, PY1
Chaouat, A1
Devillier, P1
Escamilla, R1
Louis, R2
Mal, H1
Muir, JF1
Pérez, T1
Similowski, T1
Wallaert, B1
Roche, N1
Cortijo Gimeno, J1
Morcillo Sánchez, E1
Meyer, T1
Reitmeir, P1
Brand, P1
Herpich, C1
Sommerer, K1
Schulze, A1
Scheuch, G1
Newman, S1
Pilette, C1
Garcia, G1
Tillie-Leblond, I1
O'Clock, GD1
Lee, YW1
Warwick, WJ1
Nofziger, C1
Vezzoli, V1
Dossena, S1
Schönherr, T1
Studnicka, J1
Nofziger, J1
Vanoni, S1
Stephan, S1
Silva, ME1
Meyer, G1
Paulmichl, M1
Martins, JA1
Dornelas de Andrade, A1
Britto, RR1
Lara, R1
Parreira, VF1
Ganesan, S1
Faris, AN1
Comstock, AT1
Sonstein, J1
Sajjan, US1
Tilley, P1
Sales Luis, JP1
Branco Ferreira, M1
Miravitlles, M1
Calle, M1
Soler-Cataluña, JJ1
Chakravorty, I1
Chahal, K1
Austin, G1
Cao, L1
Chen, Y1
Zhang, H1
Jiang, DP1
Li, Q1
P Kolosov, V1
M Perelman, J1
Sadowska, AM1
Yamaya, M2
Azuma, A1
Takizawa, H1
Kadota, J1
Kudoh, S1
Yang, SQ1
Li, JX1
Lou, BD1
Li, XP1
Huang, XH1
Liu, XP1
Yang, LB1
Shi, WY1
Cao, Y1
Iwashita, H1
Fujimoto, K1
Morita, S1
Nakanishi, A1
Kubo, K1
Nie, YC1
Wu, H1
Li, PB1
Luo, YL1
Zhang, CC1
Shen, JG1
Su, WW1
Tam, A1
Sin, DD2
Tao, B1
Wang, D1
Cheng, H1
Wang, K5
Zhou, R1
Xie, Q1
Ke, Y1
Venturelli, E1
Crisafulli, E1
DeBiase, A1
Righi, D1
Berrighi, D1
Cavicchioli, PP1
Vagheggini, G1
Dabrosca, F1
Balbi, B1
Paneroni, M1
Bianchi, L1
Vitacca, M1
Galimberti, V1
Zaurino, M1
Schiavoni, G1
Iattoni, A1
Ambrosino, N1
Clini, EM1
Alevy, YG1
Patel, AC1
Patel, DA1
Tucker, J1
Roswit, WT1
Miller, CA1
Heier, RF1
Basbaum, C1
Salathe, M1
Forteza, R1
Conner, GE1
Barnes, PJ4
Disse, B1
Ishihara, Y1
Kagawa, J1
Pistelli, R2
Miller, DL1
Tennant, RC1
Erin, EM1
Hansel, TT1
Laufs, J1
Andrason, H1
Sigvaldason, A1
Halapi, E1
Thorsteinsson, L1
Jónasson, K1
Söebech, E1
Gislason, T2
Gulcher, JR1
Stefansson, K1
Hakonarson, H1
Morgan, L1
Pearson, M1
de Iongh, R1
Mackey, D1
van der Wall, H1
Peters, M1
Rutland, J1
Maestrelli, P1
Baldari, F1
Sammarro, S1
Piatti, G1
Ambrosetti, U1
Santus, P1
Allegra, L1
Parnham, MJ1
Bai, TR1
Stockley, RA1
Spurzem, JR1
Rennard, SI1
Vargas, F1
Bui, HN1
Boyer, A1
Salmi, LR1
Gbikpi-Benissan, G1
Guenard, H1
Gruson, D1
Hilbert, G1
Hogg, JC2
Gendler, SJ1
Rose, MC1
Berezhnova, IA1
Korshunov, GV1
Shishkova, NI1
Zhirkova, NN1
Djukanovic, R1
Gosens, R1
Zaagsma, J1
Meurs, H1
Halayko, AJ1
de Marco, R1
Accordini, S1
Corsico, A1
Antó, JM1
Künzli, N1
Janson, C1
Sunyer, J1
Jarvis, D1
Chinn, S1
Vermeire, P1
Svanes, C1
Ackermann-Liebrich, U1
Heinrich, J1
Leynaert, B1
Neukirch, F1
Schouten, JP1
Wjst, M1
Burney, P1
Randell, SH1
Sampsonas, F1
Karkoulias, K1
Kaparianos, A1
Spiropoulos, K1
Jay, AN1
Shah, SA1
Park, JA1
Adler, KB1
Danahay, H1
Jackson, AD3
Qiu, Y2
Valobra, M1
Qiu, S1
Majumdar, S2
Matin, D1
De Rose, V2
Jeffery, PK2
Chu, FS1
Tan, WC1
Patel, SA1
Rogers, RM1
Cherniack, RM1
Sharafkhaneh, A1
Luketich, JD1
Coxson, HO1
Elliott, WM1
Sciurba, FC1
Feng, YL3
Wen, FQ4
Chen, XR2
Ou, XM3
Yang, J3
Deng, ZP3
Crimi, E1
Pellegrino, R1
Restrepo, RD1
van der Schans, CP1
López-Boado, YS1
Solomatin, VP1
Bredikhina, NA1
Nakao, I1
Kanaji, S1
Ohta, S1
Matsushita, H1
Arima, K1
Yuyama, N1
Nakayama, K1
Kubo, H1
Watanabe, M1
Sagara, H1
Sugiyama, K1
Tanaka, H1
Toda, S1
Hayashi, H1
Inoue, H1
Hoshino, T1
Shiraki, A1
Inoue, M1
Suzuki, K1
Aizawa, H1
Okinami, S1
Nagai, H1
Hasegawa, M1
Fukuda, T1
Green, ED1
Izuhara, K1
Ansari, T1
Oliva, A1
Kips, JC1
Pauwels, RA1
Kirkham, S1
Sheehan, JK1
Knight, D1
Richardson, PS1
Thornton, DJ1
Tigani, B2
Schaeublin, E1
Sugar, R2
Fozard, JR2
Beckmann, N2
Heijdra, YF1
Pinto-Plata, VM1
Kenney, LA1
Rassulo, J1
Celli, BR1
Leikauf, GD1
Borchers, MT1
Prows, DR1
Simpson, LG1
Melton, L1
Jones, G1
Mazzoni, L1

Clinical Trials (27)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructiv[NCT03034967]Phase 2614 participants (Actual)Interventional2017-04-25Completed
Subpopulations and Intermediate Outcome Measures in COPD Study[NCT01969344]2,981 participants (Actual)Observational2010-11-30Active, not recruiting
Severe Asthma Research Program (SARP) - University of Wisconsin[NCT01760915]107 participants (Actual)Observational2012-11-28Completed
Clinical and Molecular Phenotypes of Severe Asthma[NCT01718197]151 participants (Actual)Observational2012-11-30Completed
A Two-arm, Placebo-controlled, Randomized Clinical Trial to Evaluate the Effect of Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma[NCT05280418]Phase 330 participants (Anticipated)Interventional2022-11-08Recruiting
Severe Asthma Research Program[NCT01606826]1,100 participants (Anticipated)Observational2012-10-31Active, not recruiting
Severe Asthma Research Program[NCT01759186]300 participants (Anticipated)Observational2012-12-31Active, not recruiting
Severe Asthma Research Program (SARP)-Washington University[NCT01716494]121 participants (Actual)Observational2012-10-31Active, not recruiting
The Severe Asthma Research Program at Wake Forest University - Longitudinal Phenomics and Genetics of Severe Asthma.[NCT01750411]87 participants (Actual)Observational2012-12-31Completed
ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III[NCT01761630]126 participants (Actual)Observational2012-12-31Completed
"Validation of a Questionnaire to Assess Bronchial Mucus Hypersecretion in Asthmatic Patients. Questionnaire T-sec (Secretion Test)."[NCT05546645]100 participants (Anticipated)Observational2023-10-01Recruiting
Comparative Effects of Costophrenic Assisted Cough and Anterior Chest Compression Technique on Sputum Diary, Oxygen Saturation, Expiratory Flow Rate, and Dyspnea in Patients With Chronic Obstructive Pulmonary Disease[NCT05922241]34 participants (Actual)Interventional2023-06-15Completed
A Prospective Safety and Feasibility Study of the RejuvenAir™ System Metered Cryospray Therapy for Chronic Bronchitis Patients[NCT02483637]30 participants (Actual)Interventional2016-02-29Completed
Comparative Effects of Anterior Chest Compression Assist and Abdominal Thrust Assist Technique on Sputum Diary, Oxygen Saturation, Expiratory Flow Rate, and Dyspnea in Patients With Chronic Obstructive Pulmonary Disease[NCT05936801]34 participants (Anticipated)Interventional2023-07-15Not yet recruiting
The Efficacy of the AIRVO Warm Humidifier as an Add on to Oxygen Therapy as Well as Stand-alone Therapy in Patients With Respiratory Insufficiency[NCT03081650]30 participants (Anticipated)Interventional2016-08-16Recruiting
Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula on Nasal Mucociliary Clearance, Mucus Properties, Inflammation and Airway Symptoms in Patients[NCT02515786]Phase 1/Phase 219 participants (Anticipated)Interventional2013-01-31Active, not recruiting
Clinical and Physiological Effects of Exercise Training in Symptomatic Patients With Mild COPD[NCT02930421]30 participants (Actual)Interventional2015-03-31Completed
A Double-blind, Placebo Controlled, Randomized Crossover Trial to Characterize the Mucolytic Effectiveness of Tacholiquine® in Chronic Bronchitis[NCT02515799]Phase 427 participants (Actual)Interventional2014-08-31Completed
Role of Cough Assist Device in Mechanically Ventilated Patients in Respiratory Intensive Care Unit : Assiut University Experience[NCT05480371]200 participants (Anticipated)Interventional2022-08-01Not yet recruiting
Efficacy and Safety of Fluticasone Furoate/Vilanterol vs. Umeclidinium/Vilanterol in Patients With COPD-asthma Phenotype vs. Emphysema Phenotype. A Controled Clinical Trial.[NCT05342558]Phase 4133 participants (Actual)Interventional2017-09-19Completed
Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management[NCT04628962]250 participants (Anticipated)Observational2022-02-01Recruiting
Self-Administered High Frequency Chest Wall Oscillation Technique for Mucus Clearance in COPD: An Exploratory Pilot Project Using the SMARTVEST Device[NCT00863616]32 participants (Actual)Interventional2006-08-31Completed
Comparison Of Blow Bottle Positive Expiratory Pressure (BBPEP) Versus Acapella on Oxygenation ,Peak Expiratory Flow Rate (PEFR) Among Patient With Chronic Bronchitis[NCT06086730]36 participants (Actual)Interventional2023-07-20Completed
Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD- A Multicenter Randomized Controlled Double-blind Study[NCT04061161]Phase 450 participants (Anticipated)Interventional2019-08-19Recruiting
The Feasibility and Efficacy of Heated Humidified Nasal Cannula (AIRVOTM) in Hospital and at Home - An Open-Label, Non-Randomized Pilot Study.[NCT03772626]30 participants (Anticipated)Interventional2019-02-25Active, not recruiting
The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and Dyspnea is Associated to the Improvement in Small Airway Dysfunction in COPD Patients. A Pilot Study (IOSCOPD20161102)[NCT04421742]43 participants (Actual)Observational2017-05-31Completed
Effectiveness of Respiratory Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease[NCT02125747]35 participants (Actual)Interventional2011-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Respiratory Symptoms Measured by E-RS in COPD (E-RS: COPD Breathlessness Score)

E-RS: COPD is a subset of EXACT. E-RS is a tool that consists of 11 items from the 14 item EXACT instrument. The domains include: RS-BRL comprised of 5 items, score range (0-17), RS-CSP comprised of 3 items, score range (0-11), and RS-CSY comprised of 3 items, score range (0-12). The total score ranged between 0-40 and higher values indicates severe respiratory symptoms. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Posterior mean change and standard deviation has been presented. (NCT03034967)
Timeframe: Baseline and Month 6

InterventionScores on a scale (Mean)
Placebo-0.82
Danirixin 5 mg-0.69
Danirixin 10 mg-0.41
Danirixin 25 mg-0.15
Danirixin 35 mg-0.10
Danirixin 50 mg-0.09

Change From Baseline in Respiratory Symptoms Measured by E-RS in COPD (E-RS: COPD Chest Symptoms Score)

E-RS: COPD is a subset of EXACT. E-RS is a tool that consists of 11 items from the 14 item EXACT instrument. The domains include: RS-BRL comprised of 5 items, score range (0-17), RS-CSP comprised of 3 items, score range (0-11), and RS-CSY comprised of 3 items, score range (0-12). The total score ranged between 0-40 and higher values indicates severe respiratory symptoms. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Posterior mean change and standard deviation has been presented. (NCT03034967)
Timeframe: Baseline and Month 6

InterventionScores on a scale (Mean)
Placebo-0.36
Danirixin 5 mg-0.35
Danirixin 10 mg-0.34
Danirixin 25 mg-0.34
Danirixin 35 mg-0.34
Danirixin 50 mg-0.34

Change From Baseline in Respiratory Symptoms Measured by E-RS in COPD (E-RS: COPD Cough and Sputum Score)

E-RS: COPD is a subset of EXACT. E-RS is a tool that consists of 11 items from the 14 item EXACT instrument. The domains include: RS-BRL comprised of 5 items, score range (0-17), RS-CSP comprised of 3 items, score range (0-11), and RS-CSY comprised of 3 items, score range (0-12). The total score ranged between 0-40 and higher values indicates severe respiratory symptoms. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Posterior mean change and standard deviation has been presented. (NCT03034967)
Timeframe: Baseline and Month 6

InterventionScores on a scale (Mean)
Placebo-0.83
Danirixin 5 mg-0.79
Danirixin 10 mg-0.67
Danirixin 25 mg-0.46
Danirixin 35 mg-0.40
Danirixin 50 mg-0.37

Change From Baseline in Respiratory Symptoms Measured by Evaluating Respiratory Symptoms (E-RS) in COPD. E-RS: COPD Total Score

E-RS: COPD is a subset of Exacerbations of Chronic pulmonary Disease Tool (EXACT). E-RS is a tool that consists of 11 items from the 14 item EXACT instrument. The domains include: respiratory symptoms (RS)-breathlessness (RS-BRL comprised of 5 items, score range [0-17]), RS-cough and sputum (RS-CSP comprised of 3 items, score range [0-11]), and RS-chest symptoms (RS-CSY comprised of 3 items, score range [0-12]). The total score ranged between 0-40 and higher values indicates severe respiratory symptoms. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Per protocol population included all participants from the mITT population who did not have a protocol deviation considered to impact efficacy. Posterior mean change and standard deviation has been presented. (NCT03034967)
Timeframe: Baseline and Month 6

InterventionScores on a scale (Mean)
Placebo-2.11
Danirixin 5 mg-1.93
Danirixin 10 mg-1.47
Danirixin 25 mg-0.87
Danirixin 35 mg-0.76
Danirixin 50 mg-0.71

EXACT Event Duration for All Events

EXACT is a 14 item PRO instrument designed to capture information on the occurrence, frequency, severity, and duration of exacerbations of disease in participants with COPD. The total score for EXACT-PRO ranges from 0-100, higher scores indicate more severe symptoms. Severity is the highest EXACT total score during the period from onset to recovery. Duration of EXACT events has been reported. (NCT03034967)
Timeframe: Up to Day 168

InterventionDays (Mean)
Placebo45.3
Danirixin 5 mg11.6
Danirixin 10 mg45.8
Danirixin 25 mg25.5
Danirixin 35 mg17.6
Danirixin 50 mg18.7

HCRU-defined Exacerbation Duration

The duration of HCRU exacerbation were determined. The duration of the exacerbation was calculated as (exacerbation resolution date or date of death - exacerbation onset date + 1). For exacerbations which were not resolved but where the participant later died from other causes, the duration was calculated using date of death as the end date of the event. (NCT03034967)
Timeframe: Up to Day 196

InterventionDays (Mean)
Placebo10.3
Danirixin 5 mg12.3
Danirixin 10 mg12.9
Danirixin 25 mg14.0
Danirixin 35 mg10.7
Danirixin 50 mg14.2

Number of Responders E-RS in COPD (E-RS): COPD Total Score

E-RS: COPD is a subset of EXACT. E-RS is a tool that consists of 11 items from the 14 item EXACT instrument. E-RS is intended to capture information related to the respiratory symptoms of COPD, i.e. breathlessness, cough, sputum production, chest congestion and chest tightness. The E-RS has a scoring range of 0-40; higher scores indicate more severe symptoms. Response is defined as an E-RS: COPD total score of 2 units below baseline or lower. Non-response is defined as an E-RS: COPD total score higher than 2 units below Baseline. (NCT03034967)
Timeframe: Month 6

InterventionParticipants (Number)
Placebo33
Danirixin 5 mg48
Danirixin 10 mg33
Danirixin 25 mg30
Danirixin 35 mg29
Danirixin 50 mg32

Percent Predicted Normal FEV1

Spirometric analysis was done to determine percent predicted FEVI at screening. FEV1 is forced expiratory volume in one second. Percent predicted FEV1 is defined as the percent FEV1 of the participant is divided by average FEV1 percent in the population of any person similar age, sex and body composition. (NCT03034967)
Timeframe: At Screening

InterventionPercent predicted FEV1 (Mean)
Placebo58.98
Danirixin 5 mg56.75
Danirixin 10 mg56.62
Danirixin 25 mg56.84
Danirixin 35 mg57.51
Danirixin 50 mg57.84

Severity of EXACT Event

EXACT is a 14 item PRO instrument designed to capture information on the occurrence, frequency, severity, and duration of exacerbations of disease in participants with COPD. The total score for EXACT-PRO ranges from 0-100, higher scores indicate more severe symptoms. Severity is the highest EXACT total score during the period from onset to recovery. (NCT03034967)
Timeframe: Up to Day 168

InterventionScores on a scale (Mean)
Placebo22.1
Danirixin 5 mg26.7
Danirixin 10 mg22.9
Danirixin 25 mg28.6
Danirixin 35 mg25.0
Danirixin 50 mg26.4

Area Under the Plasma Concentration-time Curve From Time Zero to Last Time of Quantifiable Concentration [AUC(0-t)] of Danirixin in Whole Blood Using Dried Blood Spot

Blood samples were collected at indicated timepoints for the analysis of phamacokinetic parameter. All participants in the PK population who had at least 1 non-missing PK assessment obtained and analyzed whilst on treatment with danirixin from a dry blood spot sample and corresponding wet whole blood sample were included in Pharmacokinetic population. (NCT03034967)
Timeframe: Days 1 and 168

,,,,
InterventionHour*nanogram per milliliter (Geometric Mean)
Day 1, n=17, 19, 24, 26, 19Day 168, n=14, 13, 17, 18, 16
Danirixin 10 mg1373.11701.8
Danirixin 25 mg3851.54170.1
Danirixin 35 mg5485.17682.6
Danirixin 5 mg543.0752.1
Danirixin 50 mg8073.411538.0

Change From Baseline COPD Assessment Test (CAT) Total Score

The CAT is an 8 item questionnaire (cough, sputum, chest tightness, breathlessness, going up hills/stairs, activity limitation at home, confidence leaving the home, and sleep and energy) that measures health status of participants with COPD. Participants were completed each question by rating their experience on a 6 point scale ranging from 0 (maximum impairment) to 5 (no impairment) with a total scoring range of 0-40; higher scores indicate worse health status. A CAT score was calculated by summing the non-missing scores on the eight items. Individual items are scored from 0 to 5 with a total score range from 0 - 40, higher scores indicate greater disease impact. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Posterior mean change and standard deviation has been presented. (NCT03034967)
Timeframe: Baseline, Days 84 and 168

,,,,,
InterventionScores on a scale (Mean)
Day 84, n=89, 97, 92, 89, 88, 85Day 168, n=84, 94, 86, 87, 85, 83
Danirixin 10 mg-0.63-1.23
Danirixin 25 mg-0.55-0.97
Danirixin 35 mg-1.51-1.56
Danirixin 5 mg-0.86-1.39
Danirixin 50 mg-0.36-1.32
Placebo-2.02-1.39

Change From Baseline in Post-bronchodilator FEV1 as a Lung Function Assessment

Spirometric analysis was done to determine FEV1. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Least square mean change from Baseline and standard error has been presented. (NCT03034967)
Timeframe: Baseline, Days 84 and 168

,,,,,
InterventionLiters (Least Squares Mean)
Day 84, n=94, 99, 98, 97, 92, 93Day 168, n=88, 97, 90, 90, 88, 86
Danirixin 10 mg-0.029-0.033
Danirixin 25 mg-0.018-0.058
Danirixin 35 mg-0.027-0.012
Danirixin 5 mg-0.031-0.043
Danirixin 50 mg0.027-0.011
Placebo0.016-0.016

Change From Baseline in Post-bronchodilator FEV1/FVC Ratio as a Lung Function Assessment

Spirometric analysis was done to determine FEV1 and FVC. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. (NCT03034967)
Timeframe: Baseline, Days 84 and 168

,,,,,
InterventionRatio of FEV1/FVC (Mean)
Day 84, n=94, 99, 98, 97, 92, 93Day 168, n=88, 97, 90, 90, 88, 86
Danirixin 10 mg-0.0000.003
Danirixin 25 mg-0.013-0.015
Danirixin 35 mg-0.0000.002
Danirixin 5 mg-0.001-0.003
Danirixin 50 mg0.014-0.002
Placebo-0.003-0.007

Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC) as a Lung Function Assessment

Spirometric analysis was done to determine FVC. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Least square mean change from Baseline and standard error has been presented. (NCT03034967)
Timeframe: Baseline, Days 84 and 168

,,,,,
InterventionLiters (Least Squares Mean)
Day 84, n=94, 99, 98, 97, 92, 93Day 168, n=88, 97, 90, 90, 88, 86
Danirixin 10 mg-0.043-0.043
Danirixin 25 mg0.027-0.024
Danirixin 35 mg-0.049-0.036
Danirixin 5 mg-0.054-0.079
Danirixin 50 mg0.014-0.016
Placebo0.024-0.011

Change From Baseline in St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Total Score

The SGRQ-C consists of 40 items aggregated into 3 component scores: Symptoms, Activity, Impacts, and a Total score. Each response to a question is assigned a weight. Component scores are calculated by summing the weights from all positive items in that component, dividing by the sum of weights for all items in that component, and multiplying this number by 100. Component scores could range from 0-100, with a higher component score indicating greater disease burden. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Posterior mean change and standard deviation has been presented. (NCT03034967)
Timeframe: Baseline, Days 84 and 168

,,,,,
InterventionScores on a scale (Mean)
Day 84, n=93, 97, 94, 96, 91, 90Day 168, n=85, 96, 86, 90, 86, 85
Danirixin 10 mg-1.31-4.19
Danirixin 25 mg-3.19-4.94
Danirixin 35 mg-2.83-4.12
Danirixin 5 mg-3.63-3.44
Danirixin 50 mg-2.48-3.41
Placebo-3.79-4.11

Change From Baseline Number of Puffs of Rescue Medication Per Day

The mean number of puffs of rescue per day was calculated over the same time periods and using the same assumptions as rescue use via diary. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Least square mean change from Baseline and standard error has been presented. (NCT03034967)
Timeframe: Baseline, Months 1, 2, 3, 4, 5 and 6

,,,,,
InterventionPuffs per day (Least Squares Mean)
Month 1, n=100, 102, 100, 102, 98, 99Month 2, n=96, 100, 98, 97, 98, 96Month 3, n=95, 100, 95, 97, 94, 92Month 4, n=92, 98, 92, 97, 90, 90Month 5, n=88, 97, 88, 94, 87, 87Month 6, n=86, 95, 88, 91, 85, 86
Danirixin 10 mg0.280.180.210.270.190.10
Danirixin 25 mg0.150.350.250.210.250.15
Danirixin 35 mg-0.030.070.07-0.04-0.060.04
Danirixin 5 mg0.360.420.290.270.170.21
Danirixin 50 mg0.280.330.270.440.290.28
Placebo0.00-0.22-0.18-0.18-0.16-0.17

Concentration Maximum (Cmax) of Danirixin in Whole Blood Using Dried Blood Spots

Blood samples were collected from the participants for the analysis of pharmacokinetic parameter. (NCT03034967)
Timeframe: Days 1 and 168

,,,,
InterventionNanogram per milliliter (Geometric Mean)
Day 1, n=17, 19, 24, 26, 19Day 168, n=14, 13, 17, 18, 16
Danirixin 10 mg343.1357.3
Danirixin 25 mg1028.8821.2
Danirixin 35 mg1386.21695.0
Danirixin 5 mg164.9171.9
Danirixin 50 mg2119.12390.5

Danirixin Whole Blood Pharmacokinetic Concentration-Time Data

Blood samples were collected from the participants for the analysis of blood pharmacokinetic concentration-time data. All participants in the mITT population who had at least 1 non-missing Pharmacokinetic assessment obtained and analyzed whilst on treatment with danirixin were included Pharmacokinetic population. (NCT03034967)
Timeframe: Pre-dose on Days 1, 56, 84 and 168; 0.5, 1, 2, 4, 6, 8, 10, 12 hours post-dose on Days 1 and 168

,,,,
InterventionNanogram per milliliter (Mean)
Day 1, Pre-dose, n=97, 99, 102, 102, 100Day 1, 0.5 hour, n=16, 19, 24, 26, 19Day 1, 1 hour, n=16, 18, 24, 26, 19Day 1, 2 hours, n=16, 19, 24, 26, 19Day 1, 4 hours, n=16, 19, 24, 26, 19Day 1, 6 hours, n=16, 19, 24, 26, 19Day 1, 8 hours, n=15, 19, 24, 26, 19Day 1, 10 hours, n=16, 18, 22, 26, 19Day 1, 12 hours, n=16, 16, 21, 26, 18Day 56, Pre-dose, n=94, 91, 94, 95, 92Day 84, Pre-dose, n=97, 94, 96, 91, 90Day 168, Pre-dose, n=92, 85, 89, 85, 84Day 168, 0.5 hours, n=14, 12, 17, 18, 16Day 168, 1 hours, n=14, 13, 17, 18, 16Day 168, 2 hours, n=14, 13, 17, 18, 16Day 168, 4 hours, n=13, 11, 16, 18, 16Day 168, 6 hours, n=13, 13, 16, 18, 15Day 168, 8 hours, n=13, 13, 17, 18, 15Day 168, 10 hours, n=13, 12, 17, 18, 15Day 168, 12 hours, n=13, 12, 17, 18, 15
Danirixin 10 mg0.4210.4343.3277.7165.3100.667.861.574.791.876.299.5248.3314.0331.9190.9135.5102.676.673.1
Danirixin 25 mg0.3730.5822.0707.7401.5270.0213.8265.0188.2252.3212.3217.9530.5681.2574.7452.8289.6245.1193.9169.7
Danirixin 35 mg17.2976.11183.51011.2591.5371.5325.8274.5232.8372.1342.8350.71449.51590.31045.2805.0554.8444.9380.2481.2
Danirixin 5 mg2.186.7148.3115.359.234.426.142.587.253.250.241.2147.7162.1127.490.555.641.542.442.2
Danirixin 50 mg3.91331.01846.21472.8904.6594.9428.2302.3459.3572.0484.3459.51635.61725.41736.61459.9960.4760.8715.0662.4

Number of CAT Responder

A participant was considered as a responder according to CAT score if their change from Baseline CAT score 2.0 units below Baseline or lower. (NCT03034967)
Timeframe: Day 84 and Day 168

,,,,,
InterventionParticipants (Count of Participants)
Day 84, n=89, 97, 92, 89, 88, 85Day 168, n=84, 94, 86, 87, 85, 83
Danirixin 10 mg3839
Danirixin 25 mg3742
Danirixin 35 mg4346
Danirixin 5 mg4444
Danirixin 50 mg3644
Placebo4641

Number of EXACT Events Per Participant

EXACT is a 14 item patient reported outcome (PRO) instrument designed to capture information on the occurrence, frequency, severity, and duration of exacerbations of disease in participants with COPD. The total score for EXACT-PRO ranges from 0-100, higher scores indicate more severe symptoms. Events were categorized as recovered, censored, or persistent worsening. Number of EXACT events per participant has been presented, where 0= participants in each treatment group who did not experience an event; 1= participants in each treatment group who experienced 1 event and >=2= participants in each treatment group who experienced 2 or more events. (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionEvents (Number)
01>=2
Danirixin 10 mg9271
Danirixin 25 mg9292
Danirixin 35 mg86104
Danirixin 5 mg9264
Danirixin 50 mg86103
Placebo9290

Number of Moderate or Severe Healthcare Resource Utilization (HCRU) Exacerbations Per Participant

Participants with moderate or severe COPD exacerbations, i.e. breathlessness, cough, sputum production, chest congestion and chest tightness analyzed. Mild exacerbations are defined as exacerbations that did not require treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization, Emergency Room [ER] visit or resulting in death). Moderate exacerbations are defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization, ER visit or resulting in death). Severe exacerbations are defined as exacerbations that required hospitalization, ER visit or resulted in death. Number of moderate or severe HCRU exacerbations per participant has been presented, where 0= participants in each treatment group who did not experience an event; 1= participants in each treatment group who experienced 1 event and >=2= participants in each treatment group who experienced 2 or more events. (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionExacerbations per participant (Number)
01>=2
Danirixin 10 mg612316
Danirixin 25 mg632812
Danirixin 35 mg553015
Danirixin 5 mg513417
Danirixin 50 mg503613
Placebo66287

Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE. (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionParticipants (Count of Participants)
Any AEAny SAE
Danirixin 10 mg6913
Danirixin 25 mg6810
Danirixin 35 mg637
Danirixin 5 mg637
Danirixin 50 mg7111
Placebo638

Number of Participants With Worst Case Clinical Chemistry Parameter Results by PCI

"Blood samples were collected from participants for analysis of following chemistry parameters with PCI low and high values: Alanine aminotransferase (ALT) International units per liter (IU/L) (High => 3x ULN), Alkaline phosphatase (ALP) (IU/L) (High ≥ 2x ULN); Aspartate aminotransferase (AST) (IU/L) (High=> 3x ULN); Bilirubin micromole per liter (umol/L) (High ≥ 2x ULN); Calcium millimole per liter (mmol/L) (Low 0.85x, high 1.08x), Chloride (mmol/L) (Low 0.90x, high 1.10x), Creatinine (umol/L) (High 1.30x), Direct bilirubin (umol/L) (High ≥ 2x ULN), Glucose (mmol/L) (Low <0.6x, high >4x), Potassium (mmol/L) (Low 0.75x, high 1.30x); Protein (g/L) (High 1.25x), Sodium (mmol/L) (Low 0.80x, high 1.15x), Multipliers are identified by x, otherwise actual comparison values are provided with units. Values above and below this range were considered of PCI." (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionParticipants (Count of Participants)
ALT, No change,n=99,102,102,102,101,100ALT, High, n=99,102,102,102,101,100ALP, No change,n=99,102,102,102,101,100ALP, High, n=99,102,102,102,101,100AST, No change,n=99,102,102,102,101,100AST, High, n=99,102,102,102,101,100Bilirubin, No change, n=99,102,102,102,101,100Bilirubin, High, n=99, 102,102,102,101,100Calcium, Low, n=96,102,101,101,101,99Calcium, No change, n=96,102,101,101,101,99Calcium, High, n=96,102,101,101,101,99CO2, Low, n=96,102,101,101,101,99CO2, No change, n=96,102,101,101,101,99CO2, High, n=96,102,101,101,101,99Chloride, Low, n=96,102,101,101,101,99Chloride, No change, n=96,102,101,101,101,99Chloride, High, n=96,102,101,101,101,99Creatinine, No change, n=96,102,101,101,101,99Creatinine, High, n=96, 102, 101, 101, 101, 99Direct bilirubin,NoChange,n=99,102,102,102,101,100Direct bilirubin,High,n=99,102,102,102,101,100Glucose, Low, n=96, 102, 101, 101, 101, 99Glucose, No change, n=96, 102, 101, 101, 101, 99Glucose, High, n=96, 102, 101, 101, 101, 99Potassium, Low, n=96, 102, 101, 101, 101, 99Potassium, No change, n=96, 102, 101, 101, 101, 99Potassium, High, n=96, 102, 101, 101, 101, 99Protein, No change, n=99, 102, 102, 102, 101, 100Protein, High, n=99, 102, 102, 102, 101, 100Sodium, Low, n=96, 102, 101, 101, 101, 99Sodium, No change, n=96, 102, 101, 101, 101, 99Sodium, High, n=96, 102, 101, 101, 101, 99Urea, Low, n=96, 102, 101, 101, 101, 99Urea, No change, n=96, 102, 101, 101, 101, 99Urea, High, n=96, 102, 101, 101, 101, 99Bilirubin/ALT,No change,n=99,102,102,102,101,100Bilirubin/ALT, High,n=99,102,102,102,101,100
Danirixin 10 mg10111020101110200101029900101099210200101001010102001010010101020
Danirixin 25 mg10201020102010200101019910101099210200101001010102001010010011020
Danirixin 35 mg101010101010101001010010100101099210100101001010101001010010101010
Danirixin 5 mg1020102010201011010200102001020100210200102001020102001020010111020
Danirixin 50 mg10001000100010000990198009909901000099009901000099009811000
Placebo9909909909900960194109609429810960096099009600960990

Number of Participants With Worst Case Hematology Parameter Results by Potential Clinical Importance (PCI)

"Blood samples were collected from participants for analysis of following hematology parameters with PCI low and high values: Basophils % (High 5.00x), Eosinophils % (High 2.00x), Mean corpuscular hemoglobin concentration (MCHC) gram per deciliter (g/dL) (Low 0.85x, high 1.10x), Mean corpuscular hemoglobin (MCH) picograms (pg) (Low 0.85x, high 1.20x), Mean corpuscular volume (MCV) femtoliter (fL) (low 0.25x, high 2.00x), Erythrocytes (Ery.)(10^12cells/L) (Low 0.93x, high 1.07x), Hematocrit (Ratio of 1) (Low 0.50x, high 0.50x), Hemoglobin gram per liter (g/L) (Low 0.85x, high 1.20x), Leukocytes (x10^9/L) (Low 0.70x, high 1.60x), Lymphocytes % (Low 0.80x, high 1.20x), Monocytes % (Low 0.80x, high 1.60x), Neutrophils % (Low 0.65x, high 1.50x), Platelets (x10^9cells/L) (Low 0.90x, high 1.10x). Multipliers are identified by x, otherwise actual comparison values are provided with units. Values above and below this range were considered of PCI." (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionParticipants (Count of Participants)
Basophils, No change, n=97, 102, 101, 101, 101, 99Basophils, High, n=97, 102, 101, 101, 101, 99Eosinophils,No change,n=97,102,101,101,101,99Eosinophils, High, n=97, 102, 101, 101, 101, 99Ery. MCHC, Low, n=97, 102, 101, 101, 102, 99Ery. MCHC,No change,n=97,102,101,101,102,99Ery. MCHC, High, n=97, 102, 101, 101, 102, 99Ery. MCH, Low, n=97, 102, 101, 101, 102, 99Ery. MCH, No Change, n=97, 102, 101, 101, 102, 99Ery. MCH, High, n=97, 102, 101, 101, 102, 99Ery. MCV, Low, n=97, 102, 101, 101, 102, 99Ery. MCV, No Change, n=97, 102, 101, 101, 102, 99Ery. MCV, High, n=97, 102, 101, 101, 102, 99Erythrocytes, Low, n=97, 102, 101, 101, 102, 99Erythrocytes, No change,n=97,102,101,101,102,99Erythrocytes. High, n=97, 102, 101, 101, 102, 99Hematocrit, Low, n=97, 102, 101, 101, 102, 99Hematocrit, No Change, n=97,102,101,101,102,99Hematocrit, High, n=97, 102, 101, 101, 102, 99Hemoglobin, Low, n=97, 102, 101, 101, 102, 99Hemoglobin, No change, n=97,102,101,101,102,99Hemoglobin, High, n=97, 102, 101, 101, 102, 99Leukocytes, Low, n=97, 102, 101, 101, 102, 99Leukocytes, No change, n=97,102,101,101,102,99Leukocytes, High, n=97, 102, 101, 101, 102, 99Lymphocytes, Low, n=97, 102, 101, 101, 101, 99Lymphocytes, No change, n=97,102,101,101,101,99Lymphocytes, High, n=97, 102, 101, 101, 101, 99Monocytes, No change, n=97, 102, 101, 101, 101, 99Monocytes, High, n=97, 102, 101, 101, 101, 99Neutrophils, Low, n=97, 102, 101, 101, 101, 99Neutrophils, No change, n=97,102,101,101,101,99Neutrophils, High, n=97, 102, 101, 101, 101, 99Platelets, Low, n=97, 102, 101, 101, 101, 99Platelets, No change, n=97, 102, 101, 101, 101, 99Platelets, High, n=97, 102, 101, 101, 101, 99
Danirixin 10 mg1010101001010010100101039710101029900101059609920101001001
Danirixin 25 mg10109830101001010010103971010100101001010892110101100001010
Danirixin 35 mg1010100101020010200102029910102021000010207931100139800992
Danirixin 5 mg10201011010200102001020199201020110100102079501011010201992
Danirixin 50 mg9909810990198009902970099009901980494198119800990
Placebo9709700970097009702932097019600970394097009700970

Number of Participants With Worst Case Post-Baseline Abnormal 12-lead Electrocardiogram (ECG) Findings

Triplicate 12-lead ECG obtained to measure PR, QRS, QT, and Corrected QT intervals. Only those participants with worst case post-Baseline data have been represented for abnormal - not clinical significant and abnormal - clinical significant. Day 1 was considered as Baseline. (NCT03034967)
Timeframe: Baseline and Day 168

,,,,,
InterventionParticipants (Count of Participants)
Not Clinical significantClinical significant
Danirixin 10 mg681
Danirixin 25 mg670
Danirixin 35 mg623
Danirixin 5 mg651
Danirixin 50 mg531
Placebo522

Number of Participants With Worst Case Vital Signs Parameter Results by PCI

Vital signs parameters includes systolic blood pressure (SBP) and diastolic blood pressure (DBP), pulse rate and respiration rate were measured in a semi-supine position after 5 minutes rest for the participants at indicated time points. PCI ranges for vital signs parameters were as follows: <90 to >160 millimeters of mercury (mmHg) for SBP and <40 to >110 mmHg for DBP, <35 or >120 beats per minute for heart rate and <8 or >30 breaths per minute for respiration rate. Values above and below this range were considered of PCI. (NCT03034967)
Timeframe: Up to Day 168

,,,,,
InterventionParticipants (Count of Participants)
SBP, LowSBP, No changeSBP, HighDBP, LowDBP, No changeDBP, HighPulse rate, LowPulse rate, No changePulse rate, HighRespiratory rate, LowRespiratory rate, No changeRespiratory rate, High
Danirixin 10 mg095601010099201010
Danirixin 25 mg0983010100100101010
Danirixin 35 mg0984010200102001020
Danirixin 5 mg09210010200102001020
Danirixin 50 mg1944099009810981
Placebo0933096009600960

Number of SGRQ Responder

A participant was consider Responder according to SGRQ total score if their change from Baseline SGRQ total score of 4 units below Baseline or lower. (NCT03034967)
Timeframe: Day 84 and Day 168

,,,,,
InterventionParticipants (Number)
Day 84, n=93, 97, 94, 96, 91, 90Day 168, n=85, 96, 86, 90, 86, 85
Danirixin 10 mg3540
Danirixin 25 mg4947
Danirixin 35 mg3541
Danirixin 5 mg4047
Danirixin 50 mg3834
Placebo3935

Participant Experience of Physical Activity Measured Using PROactive Physical Activity in COPD (C-PPAC) Questionnaire

The Clinical Visit PROactive Physical Activity in COPD (C-PPAC) tool is a designed for intermittent use within a clinical study. PROactive Total Score and two domain scores (amount and difficulty) are derived using data from the C-PPAC questionnaire and a physical activity monitor worn for 7 days prior to the questionnaire.C-PPAC is a 12 item questionnaire. The PROactive tools are scored from 0 to 100 with higher scores indicating greater disease impact. It was implemented in a subset of approximately 50% of participants. The amount domain is calculated using 2 items from the C-PPAC questionnaire (amount of walking outside and chores outside) and 2 activity monitor outputs (vector magnitude units per minute (VMU/min) and steps/day). Each domain score is based on the addition of items (0-15 for amount and 0-40 for difficulty) and then scaled from 0-100. The total score is calculated as (amount+difficulty)/2. (NCT03034967)
Timeframe: Days 84 and 168

,,,,,
InterventionScores on a scale (Mean)
Total score, Day 84, n=8, 4, 6, 6, 10, 6Total score, Day 168, n=13, 7, 9, 8, 6, 7Amount score, Day 84, n=8, 4, 6, 6, 10, 6Amount score, Day 168, n=13, 7, 9, 8, 6, 7Difficult score, Day 84, n=29, 22, 18, 19, 24, 14Difficult score, Day 168, n=29, 20, 18, 19, 25, 15
Danirixin 10 mg-3.832.11-4.002.11-0.172.11
Danirixin 25 mg0.421.250.001.251.890.63
Danirixin 35 mg-1.204.08-4.203.672.791.52
Danirixin 5 mg-5.751.86-8.50-0.431.642.20
Danirixin 50 mg2.330.43-0.83-4.144.504.87
Placebo3.00-0.962.25-3.696.383.03

Time to First EXACT Event

The time to first on-treatment EXACT event was calculated as the onset date of the first on-treatment EXACT event minus date of start of treatment plus 1. (NCT03034967)
Timeframe: Up to Day 168

,,,,,
InterventionDays (Number)
First quartile (Q1) time to eventMedian time to event
Danirixin 10 mgNANA
Danirixin 25 mgNANA
Danirixin 35 mgNANA
Danirixin 5 mgNANA
Danirixin 50 mgNANA
PlaceboNANA

Time to First HCRU-defined COPD Exacerbation

The time to first on-treatment Moderate/Severe HCRU exacerbation was calculated as exacerbation onset date of first on-treatment moderate or severe on-treatment exacerbation - date of start of treatment +1. (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionDays (Number)
Q1 time to eventMedian time to event
Danirixin 10 mg63NA
Danirixin 25 mg79NA
Danirixin 35 mg70NA
Danirixin 5 mg47NA
Danirixin 50 mg57152
Placebo110NA

Time to First Severe HCRU-defined COPD Exacerbation

A COPD exacerbation defined as a severe exacerbation if it requires hospitalization or ER visit or extended observation. The time to first on-treatment Moderate/Severe HCRU exacerbation was calculated as exacerbation onset date of first on-treatment moderate or severe on-treatment exacerbation - date of start of treatment +1. (NCT03034967)
Timeframe: Up to Day 196

,,,,,
InterventionDays (Number)
Q1 time to eventMedian time to event
Danirixin 10 mgNANA
Danirixin 25 mgNANA
Danirixin 35 mgNANA
Danirixin 5 mgNANA
Danirixin 50 mgNANA
PlaceboNANA

Time to Reach Maximum Plasma Concentration (Tmax) of Danirixin in Whole Blood Using Dried Blood Spots

Blood samples were collected from the participants for the analysis of pharmacokinetic parameter. (NCT03034967)
Timeframe: Days 1 and 168

,,,,
InterventionHours (Median)
Day 1, n=17, 19, 24, 26, 19Day 168, n=14, 13, 17, 18, 16
Danirixin 10 mg1.0001.000
Danirixin 25 mg1.0001.000
Danirixin 35 mg1.0001.000
Danirixin 5 mg1.0001.000
Danirixin 50 mg1.0001.542

Reviews

73 reviews available for guaifenesin and Airflow Obstruction, Chronic

ArticleYear
Role of mucolytics in wet cough.
    The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:5 Suppl

    Topics: Ambroxol; Asthma; Bronchodilator Agents; Cholinergic Antagonists; Cough; Cystic Fibrosis; Expectoran

2013
Physiology and pathophysiology of human airway mucus.
    Physiological reviews, 2022, 10-01, Volume: 102, Issue:4

    Topics: Cystic Fibrosis; Humans; Lung; Mucociliary Clearance; Mucus; Pulmonary Disease, Chronic Obstructive

2022
Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine!
    Cells, 2022, 02-25, Volume: 11, Issue:5

    Topics: Cystic Fibrosis; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive; Sputum

2022
Nanocarrier-based approaches to combat chronic obstructive pulmonary disease.
    Nanomedicine (London, England), 2022, Volume: 17, Issue:24

    Topics: Asthma; Chronic Disease; Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2022
Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers.
    International journal of pharmaceutics, 2023, Mar-05, Volume: 634

    Topics: Asthma; Cystic Fibrosis; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive

2023
Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment.
    Mediators of inflammation, 2023, Volume: 2023

    Topics: Cough; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive; Sputum

2023
The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease.
    Molecules (Basel, Switzerland), 2020, Sep-27, Volume: 25, Issue:19

    Topics: Bronchi; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Interleukin-13; Mucin 5AC; Muc

2020
Application of text mining to develop AOP-based mucus hypersecretion genesets and confirmation with in vitro and clinical samples.
    Scientific reports, 2021, 03-17, Volume: 11, Issue:1

    Topics: Adverse Outcome Pathways; Cigarette Smoking; Data Mining; Electronic Nicotine Delivery Systems; Huma

2021
Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.
    International journal of chronic obstructive pulmonary disease, 2017, Volume: 12

    Topics: Antioxidants; China; Consensus; Disease Progression; Expectorants; Humans; Lung; Mucociliary Clearan

2017
Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases.
    American journal of respiratory cell and molecular biology, 2018, Volume: 58, Issue:3

    Topics: Asthma; Cystic Fibrosis; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Histone C

2018
Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).
    International journal of chronic obstructive pulmonary disease, 2018, Volume: 13

    Topics: Animals; Asthma; Bronchiectasis; China; Consensus; Cystic Fibrosis; Drainage; Expectorants; Humans;

2018
Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.
    Respiratory research, 2018, 08-06, Volume: 19, Issue:1

    Topics: Animals; Asthma; Cystic Fibrosis; Humans; Mucus; Neuropeptides; Pulmonary Disease, Chronic Obstructi

2018
The pathology of small airways disease in COPD: historical aspects and future directions.
    Respiratory research, 2019, Mar-04, Volume: 20, Issue:1

    Topics: Airway Remodeling; Animals; Disease Progression; Forecasting; Humans; Inflammation; Lung; Mucus; Pul

2019
Mucus and mucins in diseases of the intestinal and respiratory tracts.
    Journal of internal medicine, 2019, Volume: 285, Issue:5

    Topics: Colitis, Ulcerative; Cystic Fibrosis; Humans; Mucins; Mucus; Pulmonary Disease, Chronic Obstructive

2019
Cellular and molecular biology of airway mucins.
    International review of cell and molecular biology, 2013, Volume: 303

    Topics: Amino Acid Sequence; Animals; Humans; Molecular Sequence Data; Mucins; Mucus; Pulmonary Disease, Chr

2013
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Expectorants; Goblet Cells; Humans; Lung; Mucociliary Cl

2014
Susceptibility to chronic mucus hypersecretion, a genome wide association study.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Cells, Cultured; Chronic Disease; Cohort Studies; Female; Genome-Wid

2014
Targeting mucus hypersecretion: new therapeutic opportunities for COPD?
    Drugs, 2014, Volume: 74, Issue:10

    Topics: Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Respiratory System

2014
Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD.
    The European respiratory journal, 2015, Volume: 45, Issue:1

    Topics: Alleles; Biopsy; Bronchi; Cohort Studies; Gene Expression Profiling; Genome-Wide Association Study;

2015
CLCA1 and TMEM16A: the link towards a potential cure for airway diseases.
    Expert review of respiratory medicine, 2015, Volume: 9, Issue:5

    Topics: Anoctamin-1; Asthma; Cell Transdifferentiation; Chloride Channels; Epithelial Cells; Humans; Mucus;

2015
Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases.
    Pharmacology, 2016, Volume: 97, Issue:1-2

    Topics: Airway Remodeling; Asthma; Chloride Channels; Ellagic Acid; ErbB Receptors; GABA Antagonists; Ginkgo

2016
Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Annals of the American Thoracic Society, 2016, Volume: 13 Suppl 2

    Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Mucus; Nicotiana; Oxid

2016
Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Annals of the American Thoracic Society, 2016, Volume: 13 Suppl 2

    Topics: Animals; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dehydration; Epitheli

2016
Airway mucus: the good, the bad, the sticky.
    Pharmacology & therapeutics, 2009, Volume: 121, Issue:3

    Topics: Cystic Fibrosis; Exocytosis; Gene Expression Regulation; Humans; Lung; Mucins; Mucus; Pulmonary Dise

2009
Mucins, mucus, and sputum.
    Chest, 2009, Volume: 135, Issue:2

    Topics: Asthma; Bronchitis, Chronic; Cystic Fibrosis; Female; Humans; Male; Mucins; Mucociliary Clearance; M

2009
A clinical practice guideline for physiotherapists treating patients with chronic obstructive pulmonary disease based on a systematic review of available evidence.
    Clinical rehabilitation, 2009, Volume: 23, Issue:5

    Topics: Dyspnea; Electric Stimulation Therapy; Exercise; Exercise Tolerance; Health Behavior; Humans; Motor

2009
Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis.
    Pharmacology & therapeutics, 2009, Volume: 124, Issue:1

    Topics: Apoptosis; Bronchitis; Cost of Illness; Humans; Immunity, Innate; Mucus; Neutrophil Activation; Neut

2009
Current perspectives of oxidative stress and its measurement in chronic obstructive pulmonary disease.
    COPD, 2010, Volume: 7, Issue:4

    Topics: Antioxidants; Apoptosis; Biomarkers; Histone Acetyltransferases; Humans; Inflammation; Lung; Mucus;

2010
New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.
    Journal of aerosol medicine and pulmonary drug delivery, 2010, Volume: 23, Issue:4

    Topics: Animals; Asthma; Cyclooxygenase 2; Cytokines; Drug Delivery Systems; Goblet Cells; Humans; Hyperplas

2010
Pseudomonas aeruginosa: host defence in lung diseases.
    Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:7

    Topics: Animals; Biofilms; Bronchiectasis; Bronchiolitis Obliterans; Cross Infection; Cystic Fibrosis; Cytok

2010
Revisited role for mucus hypersecretion in the pathogenesis of COPD.
    European respiratory review : an official journal of the European Respiratory Society, 2010, Volume: 19, Issue:116

    Topics: Expectorants; Humans; Mucus; Pneumonia; Pulmonary Disease, Chronic Obstructive

2010
Mucoactive drugs.
    European respiratory review : an official journal of the European Respiratory Society, 2010, Volume: 19, Issue:116

    Topics: Expectorants; Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2010
Mucoactive therapy in COPD.
    European respiratory review : an official journal of the European Respiratory Society, 2010, Volume: 19, Issue:116

    Topics: Expectorants; Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2010
Airway mucus function and dysfunction.
    The New England journal of medicine, 2010, Dec-02, Volume: 363, Issue:23

    Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr

2010
Airway mucus function and dysfunction.
    The New England journal of medicine, 2010, Dec-02, Volume: 363, Issue:23

    Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr

2010
Airway mucus function and dysfunction.
    The New England journal of medicine, 2010, Dec-02, Volume: 363, Issue:23

    Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr

2010
Airway mucus function and dysfunction.
    The New England journal of medicine, 2010, Dec-02, Volume: 363, Issue:23

    Topics: Asthma; Cystic Fibrosis; Humans; Lung Diseases; Mucociliary Clearance; Mucus; Pulmonary Disease, Chr

2010
[COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms].
    Revue des maladies respiratoires, 2010, Volume: 27, Issue:10

    Topics: Airway Remodeling; Anemia; Antigens; Antioxidants; Bronchitis; Cardiovascular Diseases; Comorbidity;

2010
[Pharmacological profile of roflumilast].
    Archivos de bronconeumologia, 2010, Volume: 46 Suppl 10

    Topics: Airway Remodeling; Aminopyridines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cel

2010
[Structural abnormalities and inflammation in COPD: a focus on small airways].
    Revue des maladies respiratoires, 2011, Volume: 28, Issue:6

    Topics: Adaptive Immunity; Airway Remodeling; Apoptosis; Autoimmunity; Bronchioles; Chemotaxis, Leukocyte; C

2011
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
    Archivos de bronconeumologia, 2012, Volume: 48, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato

2012
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
    Archivos de bronconeumologia, 2012, Volume: 48, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato

2012
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
    Archivos de bronconeumologia, 2012, Volume: 48, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato

2012
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
    Archivos de bronconeumologia, 2012, Volume: 48, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato

2012
N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
    Therapeutic advances in respiratory disease, 2012, Volume: 6, Issue:3

    Topics: Acetylcysteine; Expectorants; Gene Expression Regulation; Humans; Inflammation; Mucins; Mucus; Oxida

2012
Macrolide effects on the prevention of COPD exacerbations.
    The European respiratory journal, 2012, Volume: 40, Issue:2

    Topics: Anti-Inflammatory Agents; Antiviral Agents; Azithromycin; Biofilms; Bronchodilator Agents; Clinical

2012
Pathobiologic mechanisms of chronic obstructive pulmonary disease.
    The Medical clinics of North America, 2012, Volume: 96, Issue:4

    Topics: Adaptive Immunity; Airway Remodeling; Biomarkers; Cytochrome P-450 Enzyme System; Disease Progressio

2012
Chronic bronchitis and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2013, Feb-01, Volume: 187, Issue:3

    Topics: Adrenergic beta-Agonists; Anti-Bacterial Agents; Antioxidants; Bronchitis, Chronic; Cholinergic Anta

2013
Epidemiological studies in mucus hypersecretion.
    Novartis Foundation symposium, 2002, Volume: 248

    Topics: Adult; Aged; Cohort Studies; Exocrine Glands; Exocytosis; Female; Forced Expiratory Volume; Humans;

2002
Post-secretory fate of host defence components in mucus.
    Novartis Foundation symposium, 2002, Volume: 248

    Topics: Animals; Asthma; Cattle; Cilia; Humans; Hyaluronic Acid; Kallikreins; Lactoperoxidase; Mucins; Mucus

2002
Current and future therapies for airway mucus hypersecretion.
    Novartis Foundation symposium, 2002, Volume: 248

    Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Chloride Channels; Cystic Fibrosis; Drug De

2002
Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.
    Novartis Foundation symposium, 2002, Volume: 248

    Topics: Anti-Inflammatory Agents; Biomarkers; Clinical Trials as Topic; Drug Evaluation; Exocytosis; Expecto

2002
Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity.
    The European respiratory journal. Supplement, 2003, Volume: 40

    Topics: Aged; Air Pollution; Cardiovascular Diseases; Comorbidity; Humans; Mucus; Prognosis; Pulmonary Disea

2003
Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?
    Current opinion in pharmacology, 2003, Volume: 3, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents;

2003
[Pathophysiology of chronic obstructive pulmonary disease].
    Annali dell'Istituto superiore di sanita, 2003, Volume: 39, Issue:4

    Topics: Airway Obstruction; Ciliary Motility Disorders; Humans; Inflammation Mediators; Mucus; Pulmonary Dis

2003
[Risk factors of chronic obstructive pulmonary disease].
    Annali dell'Istituto superiore di sanita, 2003, Volume: 39, Issue:4

    Topics: Air Pollution; alpha 1-Antitrypsin Deficiency; Bronchial Hyperreactivity; Diet; Humans; Hypersensiti

2003
Airway mucus hypersecretion in asthma: an undervalued pathology?
    Current opinion in pharmacology, 2004, Volume: 4, Issue:3

    Topics: Airway Obstruction; Asthma; Cytokines; Humans; Mucus; Phenotype; Pulmonary Disease, Chronic Obstruct

2004
Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.
    Current opinion in infectious diseases, 2005, Volume: 18, Issue:2

    Topics: Anti-Bacterial Agents; Asthma; Bronchiolitis; Cystic Fibrosis; Cytokines; Gene Expression; Humans; I

2005
Structural changes in the airways in asthma: observations and consequences.
    Clinical science (London, England : 1979), 2005, Volume: 108, Issue:6

    Topics: Adult; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; Child; Humans; Lung; Mucus; Muscle, S

2005
COPD: current therapeutic interventions and future approaches.
    The European respiratory journal, 2005, Volume: 25, Issue:6

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antioxidants; Bronchodil

2005
Pathogenesis of COPD.
    Seminars in respiratory and critical care medicine, 2005, Volume: 26, Issue:2

    Topics: Airway Resistance; Apoptosis; Cytokines; Environmental Pollutants; Female; Humans; Male; Mucus; Prog

2005
Convergence of the epidemiology and pathology of COPD.
    Thorax, 2006, Volume: 61, Issue:1

    Topics: Female; Forced Expiratory Volume; Humans; Male; Mucus; Pulmonary Disease, Chronic Obstructive; Pulmo

2006
Chronic mucus hypersecretion, exacerbations and natural history of COPD.
    Experimental lung research, 2005, Volume: 31 Suppl 1

    Topics: Bronchitis, Chronic; Forced Expiratory Volume; Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2005
Regulation of mucin genes in chronic inflammatory airway diseases.
    American journal of respiratory cell and molecular biology, 2006, Volume: 34, Issue:6

    Topics: Animals; Asthma; Cystic Fibrosis; Cytokines; Disease Models, Animal; Gene Expression Regulation; Hum

2006
Treatment of airway mucus hypersecretion.
    Annals of medicine, 2006, Volume: 38, Issue:2

    Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchitis, Chronic; Drug Design; Goblet Ce

2006
Is the neutrophil a worthy target in severe asthma and chronic obstructive pulmonary disease?
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2006, Volume: 36, Issue:5

    Topics: Asthma; Humans; Interleukin-5; Lung; Mucus; Neutrophils; Pulmonary Disease, Chronic Obstructive; Tre

2006
Muscarinic receptor signaling in the pathophysiology of asthma and COPD.
    Respiratory research, 2006, May-09, Volume: 7

    Topics: Acetylcholine; Animals; Asthma; Bronchodilator Agents; Cell Differentiation; Cell Proliferation; Fib

2006
Airway epithelial stem cells and the pathophysiology of chronic obstructive pulmonary disease.
    Proceedings of the American Thoracic Society, 2006, Volume: 3, Issue:8

    Topics: Bronchi; Cell Differentiation; Cell Proliferation; Humans; Hyperplasia; Metaplasia; Mucus; Pulmonary

2006
Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency.
    Current medicinal chemistry, 2006, Volume: 13, Issue:24

    Topics: Alleles; alpha 1-Antitrypsin Deficiency; Homozygote; Humans; Inflammation; Matrix Metalloproteinases

2006
The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options.
    COPD, 2005, Volume: 2, Issue:3

    Topics: Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; Respiratory System Agents

2005
The role of airway secretions in COPD--clinical applications.
    COPD, 2005, Volume: 2, Issue:3

    Topics: Expectorants; Humans; Mucins; Mucus; Physical Therapy Modalities; Pulmonary Disease, Chronic Obstruc

2005
Epithelial mucus-hypersecretion and respiratory disease.
    Current drug targets. Inflammation and allergy, 2005, Volume: 4, Issue:6

    Topics: Animals; Epithelial Cells; Goblet Cells; Humans; Inflammation Mediators; Lung Diseases; Mucus; Pulmo

2005
Physiology of airway mucus secretion and pathophysiology of hypersecretion.
    Respiratory care, 2007, Volume: 52, Issue:9

    Topics: Anti-Inflammatory Agents; Asthma; Bronchi; Cystic Fibrosis; Humans; Inhalation Exposure; Intracellul

2007
Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?
    Respiratory care, 2007, Volume: 52, Issue:9

    Topics: Administration, Inhalation; Adrenergic Agents; Bronchi; Bronchodilator Agents; Cholinergic Antagonis

2007
Conventional chest physical therapy for obstructive lung disease.
    Respiratory care, 2007, Volume: 52, Issue:9

    Topics: Bronchi; Cough; Drainage, Postural; Humans; Mucociliary Clearance; Mucus; Netherlands; Physical Ther

2007
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
    Current opinion in pharmacology, 2008, Volume: 8, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Asthma; Chronic Disease; Cystic Fibrosis; Defensins; Epithelial Cell

2008
Mucus hypersecretion in the airway.
    Chinese medical journal, 2008, Apr-05, Volume: 121, Issue:7

    Topics: Animals; Aquaporin 5; Cytokines; Gene Expression Regulation; Humans; Intracellular Signaling Peptide

2008
Mucoactive drugs for asthma and COPD: any place in therapy?
    Expert opinion on investigational drugs, 2002, Volume: 11, Issue:1

    Topics: Asthma; Clinical Trials as Topic; Deoxyribonuclease I; Expectorants; Humans; Iodides; Mucins; Mucus;

2002
Mucin apoprotein expression in COPD.
    Chest, 2002, Volume: 121, Issue:5 Suppl

    Topics: Acrolein; Animals; Gene Expression Regulation; Genetic Predisposition to Disease; Humans; Mice; Muci

2002

Trials

14 trials available for guaifenesin and Airflow Obstruction, Chronic

ArticleYear
Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease.
    Computational and mathematical methods in medicine, 2021, Volume: 2021

    Topics: Administration, Inhalation; Ambroxol; Calcium; Computational Biology; Double-Blind Method; Formotero

2021
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
    Respirology (Carlton, Vic.), 2022, Volume: 27, Issue:12

    Topics: Administration, Inhalation; Androstadienes; Bronchodilator Agents; Double-Blind Method; Drug Combina

2022
CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.
    Respiratory research, 2020, Jun-12, Volume: 21, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Dose-Response

2020
[Chronic cough in the elderly is associated with expiratory flow limitation].
    Revue des maladies respiratoires, 2013, Volume: 30, Issue:3

    Topics: Aged; Aging; Bronchitis; Chronic Disease; Cough; Exhalation; Humans; Mucus; Prevalence; Pulmonary Di

2013
Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.
    Chest, 2016, Volume: 150, Issue:2

    Topics: Aged; Aged, 80 and over; Bronchiectasis; Cough; Cytokines; Disease Progression; Epidermal Growth Fac

2016
Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.
    Chest, 2016, Volume: 150, Issue:2

    Topics: Aged; Aged, 80 and over; Bronchiectasis; Cough; Cytokines; Disease Progression; Epidermal Growth Fac

2016
Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.
    Chest, 2016, Volume: 150, Issue:2

    Topics: Aged; Aged, 80 and over; Bronchiectasis; Cough; Cytokines; Disease Progression; Epidermal Growth Fac

2016
Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.
    Chest, 2016, Volume: 150, Issue:2

    Topics: Aged; Aged, 80 and over; Bronchiectasis; Cough; Cytokines; Disease Progression; Epidermal Growth Fac

2016
Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD.
    Pulmonary pharmacology & therapeutics, 2016, Volume: 39

    Topics: Aged; Bronchodilator Agents; Cough; Female; Humans; Male; Mucociliary Clearance; Mucus; Pulmonary Di

2016
[A study of the mechanism of Qingre Huatan therapy in treatment of acute exacerbation of chronic obstructive pulmonary disease by improving airway inflammation and mucus hypersecretion].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2008, Volume: 6, Issue:8

    Topics: Aged; Ambroxol; Anti-Inflammatory Agents; Diagnosis, Differential; Drug Therapy, Combination; Drugs,

2008
Effect of Tanreqing Injection on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei.
    Chinese journal of integrative medicine, 2010, Volume: 16, Issue:2

    Topics: Acute Disease; Aged; Body Temperature; Drugs, Chinese Herbal; Female; Follow-Up Studies; Hot Tempera

2010
Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.
    Respiratory medicine, 2011, Volume: 105, Issue:6

    Topics: Administration, Inhalation; Adult; Aged; Bronchodilator Agents; Cross-Over Studies; Drug Therapy, Co

2011
Effect of slow expiration with glottis opened in lateral posture (ELTGOL) on mucus clearance in stable patients with chronic bronchitis.
    Respiratory care, 2012, Volume: 57, Issue:3

    Topics: Aged; Bronchitis; Chronic Disease; Comorbidity; Cross-Over Studies; Exhalation; Female; Glottis; Hum

2012
A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion.
    International journal of chronic obstructive pulmonary disease, 2011, Volume: 6

    Topics: Aged; Aged, 80 and over; Chest Wall Oscillation; Cross-Over Studies; England; Feasibility Studies; F

2011
[Observation of the therapeutic effect on COPD of cold phlegm blocking the lung type at stable stage treated with acupoint sticking therapy in different season].
    Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2012, Volume: 32, Issue:2

    Topics: Acupuncture Points; Adult; Aged; Aged, 80 and over; Drugs, Chinese Herbal; Female; Humans; Lung; Mal

2012
Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO® project: a multicentre randomized controlled trial.
    Clinical rehabilitation, 2013, Volume: 27, Issue:4

    Topics: Aged; Analysis of Variance; Bronchitis; Bronchitis, Chronic; Female; Humans; Inspiratory Capacity; I

2013
Intrapulmonary percussive ventilation in acute exacerbations of COPD patients with mild respiratory acidosis: a randomized controlled trial [ISRCTN17802078].
    Critical care (London, England), 2005, Volume: 9, Issue:4

    Topics: Acidosis, Respiratory; Aged; Blood Chemical Analysis; Humans; Length of Stay; Mucus; Oxygen Inhalati

2005

Other Studies

137 other studies available for guaifenesin and Airflow Obstruction, Chronic

ArticleYear
[The relationship between the lung function and the level of TNF-α in serum in COPD department of respiratory].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2010, Volume: 26, Issue:9

    Topics: Aged; Guaifenesin; Humans; Middle Aged; Pulmonary Disease, Chronic Obstructive; Respiratory Function

2010
[Compatibility characteristics of Bufei Yishen formula III in regulating chronic obstructive pulmonary disease mucus hypersecretion].
    Zhonghua wei zhong bing ji jiu yi xue, 2021, Volume: 33, Issue:11

    Topics: Animals; Drugs, Chinese Herbal; Lung; Mucus; Pulmonary Disease, Chronic Obstructive; Rats

2021
MicroRNAs Associated with Chronic Mucus Hypersecretion in COPD Are Involved in Fibroblast-Epithelium Crosstalk.
    Cells, 2022, 02-02, Volume: 11, Issue:3

    Topics: Epithelium; Fibroblasts; Humans; MicroRNAs; Mucus; Pulmonary Disease, Chronic Obstructive

2022
Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease.
    The Journal of clinical investigation, 2022, 04-15, Volume: 132, Issue:8

    Topics: Adenosine Triphosphate; Animals; Disease Models, Animal; Humans; Inflammation; Mice; Mucin 5AC; Muci

2022
Interleukin-6 neutralizing antibody attenuates the hypersecretion of airway mucus via inducing the nuclear translocation of Nrf2 in chronic obstructive pulmonary disease.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 152

    Topics: Animals; Antibodies, Neutralizing; Humans; Interleukin-6; Mice; Mucin 5AC; Mucus; NF-E2-Related Fact

2022
Mucopenetration study of solid lipid nanoparticles containing magneto sensitive iron oxide.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2022, Volume: 178

    Topics: Animals; Ferric Compounds; Liposomes; Mucus; Nanoparticles; Pulmonary Disease, Chronic Obstructive;

2022
Would chronic mucus hypersecretion affect the clinical response to medications of COPD patients?
    Respirology (Carlton, Vic.), 2022, Volume: 27, Issue:12

    Topics: Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2022
[Artificial intelligence-assisted identification of mucus plugs in asthma].
    Zhonghua yi xue za zhi, 2022, Sep-13, Volume: 102, Issue:34

    Topics: Artificial Intelligence; Asthma; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Tomography,

2022
Luminal mucus plugs are spatially associated with airway wall thickening in severe COPD and asthma: A single-centered, retrospective, observational study.
    Respiratory medicine, 2022, Volume: 202

    Topics: Aged; Asthma; Female; Humans; Lung; Male; Middle Aged; Mucus; Pulmonary Disease, Chronic Obstructive

2022
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Smoking induces shifts in cellular composition and transcriptome within the bronchial mucus barrier.
    Respirology (Carlton, Vic.), 2023, Volume: 28, Issue:2

    Topics: Biopsy; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking; Transcriptome

2023
Effects of Z-VaD-Ala-Asp-Fluoromethyl Ketone (Z-VAD-FMK) and Acetyl-Asp-Glu-Val-Asp-Aldehyde(Ac-DEVD-CHO) on Inflammation and Mucus Secretion in Mice Exposed to Cigarette Smoke.
    International journal of chronic obstructive pulmonary disease, 2023, Volume: 18

    Topics: Animals; Caspase 3; Cigarette Smoking; Inflammation; Interleukin-8; Male; Mice; Mice, Inbred C57BL;

2023
Effective-compound combination of Bufei Yishen formula III combined with ER suppress airway mucus hypersecretion in COPD rats: via EGFR/MAPK signaling.
    Bioscience reports, 2023, Nov-30, Volume: 43, Issue:11

    Topics: Animals; ErbB Receptors; Interleukin-6; Lung; Mucus; Pulmonary Disease, Chronic Obstructive; Rats; R

2023
Role of mucociliary clearance system in respiratory diseases.
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2023, Feb-28, Volume: 48, Issue:2

    Topics: Humans; Lung; Mucociliary Clearance; Mucus; Pulmonary Disease, Chronic Obstructive; Respiratory Syst

2023
Effects of Shiwei Longdanhua formula on LPS induced airway mucus hypersecretion, cough hypersensitivity, oxidative stress and pulmonary inflammation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 163

    Topics: Animals; Asthma; Chronic Disease; Cough; Hypersensitivity; Inflammation; Lipopolysaccharides; Mice;

2023
[
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023, Apr-20, Volume: 43, Issue:4

    Topics: Animals; Cigarette Smoking; Epithelial Cells; Humans; Interleukin-6; Interleukin-8; Mucus; NF-kappa

2023
Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease.
    JAMA, 2023, 06-06, Volume: 329, Issue:21

    Topics: Aged; Aged, 80 and over; Airway Obstruction; Cigarette Smoking; Female; Forced Expiratory Volume; Hu

2023
Genetic regulators of sputum mucin concentration and their associations with COPD phenotypes.
    PLoS genetics, 2023, Volume: 19, Issue:6

    Topics: Humans; Mucins; Mucus; Phenotype; Pulmonary Disease, Chronic Obstructive; Sputum

2023
TNF-α and MMPs mediated mucus hypersecretion induced by cigarette smoke: An in vitro study.
    Toxicology in vitro : an international journal published in association with BIBRA, 2023, Volume: 92

    Topics: Cigarette Smoking; Humans; Lung; Mucus; Pulmonary Disease, Chronic Obstructive; Tumor Necrosis Facto

2023
Perception and clinical practice regarding mucus clearance devices with chronic obstructive pulmonary disease: a cross-sectional study of healthcare providers in Saudi Arabia.
    BMJ open, 2023, 09-14, Volume: 13, Issue:9

    Topics: Cross-Sectional Studies; Female; Humans; Male; Mucus; Perception; Physical Therapists; Pulmonary Dis

2023
Mucus Plugs and Mortality in Patients With COPD-Reply.
    JAMA, 2023, 10-03, Volume: 330, Issue:13

    Topics: Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2023
Mucus Plugs and Mortality in Patients With COPD.
    JAMA, 2023, 10-03, Volume: 330, Issue:13

    Topics: Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2023
A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production.
    American journal of physiology. Lung cellular and molecular physiology, 2023, 12-01, Volume: 325, Issue:6

    Topics: Animals; Cytokines; Humans; Inflammation; Mitogen-Activated Protein Kinase 13; Mitogen-Activated Pro

2023
[Advances in molecular mechanism and treatment of chronic mucus hypersecretion].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2023, Dec-12, Volume: 46, Issue:12

    Topics: Chronic Disease; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Quality of Life; Risk Factor

2023
Niclosamide repurposed for the treatment of inflammatory airway disease.
    JCI insight, 2019, 08-08, Volume: 4, Issue:15

    Topics: Animals; Anoctamins; Anti-Inflammatory Agents; Asthma; Bronchi; Cell Line, Tumor; Cystic Fibrosis; D

2019
Impact of cough and mucus on COPD patients: primary insights from an exploratory study with an Online Patient Community.
    International journal of chronic obstructive pulmonary disease, 2019, Volume: 14

    Topics: Attitude to Health; Cost of Illness; Cough; Female; Humans; Male; Mucus; Needs Assessment; Patient C

2019
MiR-31-5p: A shared regulator of chronic mucus hypersecretion in asthma and chronic obstructive pulmonary disease.
    Allergy, 2020, Volume: 75, Issue:3

    Topics: Asthma; Humans; MicroRNAs; Mucus; Pulmonary Disease, Chronic Obstructive

2020
Excess mucus viscosity and airway dehydration impact COPD airway clearance.
    The European respiratory journal, 2020, Volume: 55, Issue:1

    Topics: Adult; Dehydration; Humans; Mucociliary Clearance; Mucus; Pulmonary Disease, Chronic Obstructive; Sm

2020
Systems pharmacology-based study of Tanreqing injection in airway mucus hypersecretion.
    Journal of ethnopharmacology, 2020, Mar-01, Volume: 249

    Topics: Animals; Data Analysis; Disease Models, Animal; Drugs, Chinese Herbal; Ethnopharmacology; Humans; Li

2020
Serotonin receptors 5-HTR2A and 5-HTR2B are involved in cigarette smoke-induced airway inflammation, mucus hypersecretion and airway remodeling in mice.
    International immunopharmacology, 2020, Volume: 81

    Topics: Airway Remodeling; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Humans; Injections

2020
Airway mucus accumulation in COPD: the cholinergic paradox!
    The European respiratory journal, 2020, Volume: 55, Issue:1

    Topics: Cholinergic Agents; Dehydration; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Viscosity

2020
Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
    Journal of ethnopharmacology, 2020, Jul-15, Volume: 257

    Topics: Animals; Bronchi; Cytokines; Drugs, Chinese Herbal; ErbB Receptors; Inflammation; Lung; Mucus; Phosp

2020
Mediated Drug Release from Nanovehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease.
    Angewandte Chemie (International ed. in English), 2020, 11-09, Volume: 59, Issue:46

    Topics: Animals; Anti-Bacterial Agents; Drug Carriers; Drug Liberation; Humans; Mice; Mucus; Nanoparticles;

2020
Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.
    International journal of chronic obstructive pulmonary disease, 2020, Volume: 15

    Topics: Bronchitis, Chronic; Female; Humans; Male; Mucus; Pulmonary Disease, Chronic Obstructive; Quality of

2020
Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers.
    American journal of respiratory and critical care medicine, 2021, 04-15, Volume: 203, Issue:8

    Topics: Aged; Female; Forced Expiratory Volume; Healthy Volunteers; Humans; Hypoxia; Male; Middle Aged; Mucu

2021
Mucus Plugs in Medium-sized Airways: A Novel Imaging Biomarker for Phenotyping Chronic Obstructive Pulmonary Disease.
    American journal of respiratory and critical care medicine, 2021, 04-15, Volume: 203, Issue:8

    Topics: Biomarkers; Emphysema; Humans; Hypoxia; Mucus; Pulmonary Disease, Chronic Obstructive; Smokers

2021
Influence of coexistence of mild OSA on airway mucus hypersecretion in patients with COPD.
    Journal of breath research, 2021, 02-01, Volume: 15, Issue:2

    Topics: Breath Tests; Epithelial Cells; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Sleep Apnea,

2021
Mucus plugging on computed tomography and chronic bronchitis in chronic obstructive pulmonary disease.
    Respiratory research, 2021, 04-17, Volume: 22, Issue:1

    Topics: Bronchitis; Bronchitis, Chronic; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Tomography

2021
[Progress of chronic mucus hypersecretion and chronic obstructive pulmonary disease].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2021, Jun-12, Volume: 44, Issue:6

    Topics: Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2021
Epithelium-derived IL17A Promotes Cigarette Smoke-induced Inflammation and Mucus Hyperproduction.
    American journal of respiratory cell and molecular biology, 2021, Volume: 65, Issue:6

    Topics: Animals; Cell Line; Cigarette Smoking; Disease Models, Animal; Humans; Inflammation; Interleukin-17;

2021
Identification of Mucus-Associated Molecular Subtypes of Chronic Obstructive Pulmonary Disease: A Latent Profile Analysis Based on MUC5B-Associated Genes.
    Medical science monitor : international medical journal of experimental and clinical research, 2021, Aug-14, Volume: 27

    Topics: Aged; Databases, Genetic; Female; Gene Expression; Genotype; Humans; Inflammation; Lung; Male; Mast

2021
Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease.
    Mucosal immunology, 2017, Volume: 10, Issue:3

    Topics: Animals; Epithelial Sodium Channels; Humans; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; Mucin 5

2017
Roles for Myoepithelial Cells in the Formation and Maintenance of Submucosal Glands.
    American journal of respiratory cell and molecular biology, 2017, Volume: 56, Issue:6

    Topics: Animals; Asthma; Cystic Fibrosis; Epithelial Cells; Exocrine Glands; Humans; Lung; Mucus; Pulmonary

2017
Hydrogen-rich saline inhibits tobacco smoke-induced chronic obstructive pulmonary disease by alleviating airway inflammation and mucus hypersecretion in rats.
    Experimental biology and medicine (Maywood, N.J.), 2017, Volume: 242, Issue:15

    Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Bronchoalveolar Lavage Fluid; Cytokines; Disea

2017
Airway Mucins in Chronic Obstructive Pulmonary Disease.
    The New England journal of medicine, 2017, 09-07, Volume: 377, Issue:10

    Topics: Humans; Mucins; Mucus; Pulmonary Disease, Chronic Obstructive

2017
Limax extract ameliorates cigarette smoke-induced chronic obstructive pulmonary disease in mice.
    International immunopharmacology, 2018, Volume: 54

    Topics: Animals; Cigarette Smoking; Complex Mixtures; Cytokines; Disease Models, Animal; Gastropoda; Humans;

2018
Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke.
    International immunopharmacology, 2018, Volume: 55

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cigarette Smoking; Disease Models, Animal; ErbB Recept

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction.
    The Journal of clinical investigation, 2018, 03-01, Volume: 128, Issue:3

    Topics: Adult; Asthma; Case-Control Studies; Cysteine; Elasticity; Eosinophil Peroxidase; Eosinophilia; Fema

2018
Spatiotemporal organization of cilia drives multiscale mucus swirls in model human bronchial epithelium.
    Scientific reports, 2018, 02-05, Volume: 8, Issue:1

    Topics: Asthma; Biomechanical Phenomena; Bronchi; Bronchoscopy; Case-Control Studies; Cilia; Humans; Hydrody

2018
Mucus hypersecretion in asthma is associated with rhinosinusitis, polyps and exacerbations.
    Respiratory medicine, 2018, Volume: 135

    Topics: Adult; Aged; Asthma; Cough; Disease Progression; Female; Humans; Male; Middle Aged; Mucus; Olfaction

2018
Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases.
    International journal of pharmaceutics, 2018, Jul-10, Volume: 545, Issue:1-2

    Topics: Administration, Inhalation; Aerosols; Animals; Beclomethasone; Cell Line; Drug Compounding; Drug Sta

2018
Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.
    Nature communications, 2018, 06-08, Volume: 9, Issue:1

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Animals; Bacterial Infections; Bacterial Load;

2018
Expression of airway mucus-associated proteins in rats with chronic obstructive pulmonary disease with a cold-dryness symptom pattern.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2016, Volume: 36, Issue:5

    Topics: Animals; Humans; Interleukin-6; Interleukin-8; Lung; Male; Mucin 5AC; Mucus; Pulmonary Disease, Chro

2016
Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs.
    JCI insight, 2018, 09-06, Volume: 3, Issue:17

    Topics: Animals; Bacteria; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Disease Models, Animal; Epithelial

2018
An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
    American journal of respiratory and critical care medicine, 2019, 01-15, Volume: 199, Issue:2

    Topics: Acetylcysteine; Animals; Asthma; Cystic Fibrosis; Disease Models, Animal; Dithiothreitol; Expectoran

2019
Increase in secreted airway mucins and partial Muc5b STAT6/FoxA2 regulation during Pneumocystis primary infection.
    Scientific reports, 2019, 02-14, Volume: 9, Issue:1

    Topics: Animals; Asthma; Epithelial Cells; Female; Hepatocyte Nuclear Factor 3-beta; Humans; Infant; Infant,

2019
Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment.
    International journal of pharmaceutics, 2019, May-01, Volume: 562

    Topics: Adhesiveness; Adrenergic beta-2 Receptor Agonists; Alginates; Bronchodilator Agents; Cell Line; Cell

2019
Bronchial Epithelial Calcium Metabolism Impairment in Smokers and Chronic Obstructive Pulmonary Disease. Decreased ORAI3 Signaling.
    American journal of respiratory cell and molecular biology, 2019, Volume: 61, Issue:4

    Topics: Adult; Aged; Benzamides; Bronchi; Calcium; Calcium Channels; Calcium Signaling; Cells, Cultured; Cil

2019
Obstructive inflammatory tracheal pseudomembrane.
    Archivos de bronconeumologia, 2013, Volume: 49, Issue:9

    Topics: Aged; Airway Obstruction; Anti-Inflammatory Agents; Bronchi; Combined Modality Therapy; Cough; Exuda

2013
[Mucus clearance in the respiratory tract: a new concept?].
    Medecine sciences : M/S, 2013, Volume: 29, Issue:2

    Topics: Body Fluids; Concept Formation; Gels; Humans; Models, Biological; Mucociliary Clearance; Mucus; Pulm

2013
Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2013, Volume: 84, Issue:3

    Topics: Cell Line; Cell Survival; Drug Administration Schedule; Drug Delivery Systems; Epithelial Cells; Hum

2013
New drugs offer a lifeline for COPD and other respiratory diseases. Mucus-blocking medications could save countless lives.
    DukeMedicine healthnews, 2013, Volume: 19, Issue:2

    Topics: Humans; Mitogen-Activated Protein Kinase 13; Mucus; Pulmonary Disease, Chronic Obstructive; Respirat

2013
Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease.
    American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:3

    Topics: Age Factors; Animals; Animals, Newborn; Chemotaxis; Disease Models, Animal; Epithelial Sodium Channe

2013
Chronic productive cough is associated with death in smokers with early COPD.
    COPD, 2014, Volume: 11, Issue:4

    Topics: Adult; Cough; Female; Forced Expiratory Volume; Humans; Longitudinal Studies; Male; Middle Aged; Muc

2014
The pathophysiological mechanisms underlying mucus hypersecretion induced by cold temperatures in cigarette smoke-exposed rats.
    International journal of molecular medicine, 2014, Volume: 33, Issue:1

    Topics: Animals; Bronchoalveolar Lavage Fluid; Cold Temperature; Enzyme-Linked Immunosorbent Assay; Gene Exp

2014
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:12

    Topics: Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cells, Cultured; Cilia; Cytosol; Epithe

2013
The human cathelicidin LL-37 enhances airway mucus production in chronic obstructive pulmonary disease.
    Biochemical and biophysical research communications, 2014, Jan-03, Volume: 443, Issue:1

    Topics: Aged; Antimicrobial Cationic Peptides; Cathelicidins; Cells, Cultured; Disease Progression; ErbB Rec

2014
Prevalence of night-time dyspnoea in COPD and its implications for prognosis.
    The European respiratory journal, 2014, Volume: 43, Issue:6

    Topics: Aged; Denmark; Dyspnea; Female; Humans; Male; Middle Aged; Mucus; Myocardial Ischemia; Prevalence; P

2014
A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adult; Aged; Biomarkers; Cystic Fibrosis; Diffusion; Disease Progression; Elasticity; Fourier Analys

2014
Risk factors for chronic mucus hypersecretion in individuals with and without COPD: influence of smoking and job exposure on CMH.
    Occupational and environmental medicine, 2014, Volume: 71, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cohort Studies; Dust; Environmental Exp

2014
Clinical issues of mucus accumulation in COPD.
    International journal of chronic obstructive pulmonary disease, 2014, Volume: 9

    Topics: Bronchitis, Chronic; Goblet Cells; Humans; Lung; Mucociliary Clearance; Mucus; Pulmonary Disease, Ch

2014
Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema.
    American journal of respiratory cell and molecular biology, 2014, Volume: 51, Issue:5

    Topics: Airway Obstruction; Animals; Bronchoalveolar Lavage Fluid; Cystic Fibrosis; Dehydration; Genomics; M

2014
β2-Adrenoceptor involved in smoking-induced airway mucus hypersecretion through β-arrestin-dependent signaling.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adrenergic beta-2 Receptor Antagonists; Animals; Arrestins; beta-Arrestins; Cell Line, Tumor; Humans

2014
Usefulness of the assessment of discharge accumulation in the lower airways and tracheal septum thickening in the differential diagnosis of recurrent airway obstruction (RAO) and inflammatory airway disease (IAD) in the horse.
    Polish journal of veterinary sciences, 2014, Volume: 17, Issue:2

    Topics: Animals; Female; Horse Diseases; Horses; Inflammation; Male; Mucus; Pulmonary Disease, Chronic Obstr

2014
Melatonin attenuates neutrophil inflammation and mucus secretion in cigarette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling.
    Journal of pineal research, 2015, Volume: 58, Issue:1

    Topics: Animals; Antioxidants; Cell Line, Tumor; Disease Models, Animal; Extracellular Signal-Regulated MAP

2015
Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction.
    Respiratory research, 2015, Jul-15, Volume: 16

    Topics: Aged; alpha 1-Antitrypsin; Female; Humans; Leukocyte Elastase; Male; Middle Aged; Mucin 5AC; Mucocil

2015
Morpho-Functional 1H-MRI of the Lung in COPD: Short-Term Test-Retest Reliability.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Aged; Bronchiectasis; Female; Humans; Lung; Magnetic Resonance Imaging; Male; Middle Aged; Mucus; Pe

2015
Callicarpa japonica Thunb. attenuates cigarette smoke-induced neutrophil inflammation and mucus secretion.
    Journal of ethnopharmacology, 2015, Dec-04, Volume: 175

    Topics: Animals; Bronchoalveolar Lavage Fluid; Callicarpa; Cell Line; Cell Line, Tumor; Disease Models, Anim

2015
Protein networks in induced sputum from smokers and COPD patients.
    International journal of chronic obstructive pulmonary disease, 2015, Volume: 10

    Topics: Adult; Aged; Bronchitis, Chronic; Female; Forced Expiratory Volume; Humans; Immunoglobulin A, Secret

2015
[Effect of Yifei Jianpi Recipe on Airway Inflammation and Airway Mucus Hypersecretion of Chronic Obstructive Pulmonary Disease Model Rats].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2015, Volume: 35, Issue:8

    Topics: Animals; Bronchi; Bronchoalveolar Lavage Fluid; Drugs, Chinese Herbal; Inflammation; Intercellular A

2015
Targeting airway mucus hypersecretion in chronic obstructive pulmonary disease.
    Respiratory investigation, 2015, Volume: 53, Issue:6

    Topics: ErbB Receptors; Glycoproteins; Goblet Cells; Humans; Mucins; Mucus; Prognosis; Pulmonary Disease, Ch

2015
[Improvement of Awareness and Diagnosis for Chronic Obstructive Pulmonary Disease (COPD) by General Physician. Topics: II. Diagnosis of COPD in primary care physicians].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2015, Jun-10, Volume: 104, Issue:6

    Topics: Asthma; Cough; Diagnosis, Differential; Humans; Mucus; Physicians, Primary Care; Pulmonary Disease,

2015
The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development.
    American journal of respiratory and critical care medicine, 2016, Mar-15, Volume: 193, Issue:6

    Topics: Adult; Age Factors; Aging; Chronic Disease; Disease Progression; Female; Humans; Lung; Male; Middle

2016
[Effects of simvastatin on airway inflammation and airway mucus hypersecretion in rats with chronic obstructive pulmonary disease].
    Zhonghua yi xue za zhi, 2015, Jun-09, Volume: 95, Issue:22

    Topics: Animals; Bronchi; Bronchoalveolar Lavage Fluid; Enzyme-Linked Immunosorbent Assay; Inflammation; Int

2015
[Effect of aminophylline and simvastatin on airway inflammation and mucus hypersecretion in rats with chronic obstructive pulmonary disease].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2016, Volume: 41, Issue:1

    Topics: Aminophylline; Animals; Bronchi; Bronchoalveolar Lavage Fluid; Cytokines; Inflammation; Lipopolysacc

2016
Chronic Mucus Hypersecretion and the Natural History of Chronic Obstructive Pulmonary Disease.
    American journal of respiratory and critical care medicine, 2016, Mar-15, Volume: 193, Issue:6

    Topics: Aging; Female; Humans; Lung; Male; Mucus; Pulmonary Disease, Chronic Obstructive; Smoking

2016
Assessment of in vitro COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for in vitro model use.
    Alternatives to laboratory animals : ATLA, 2016, Volume: 44, Issue:2

    Topics: Animal Experimentation; Animals; Goblet Cells; Government Regulation; Humans; Mucociliary Clearance;

2016
CFD transient simulation of the cough clearance process using an Eulerian wall film model.
    Computer methods in biomechanics and biomedical engineering, 2017, Volume: 20, Issue:2

    Topics: Computer Simulation; Cough; Humans; Male; Models, Biological; Mucus; Pulmonary Disease, Chronic Obst

2017
Pinellia ternata Attenuates Mucus Secretion and Airway Inflammation after Inhaled Corticosteroid Withdrawal in COPD Rats.
    The American journal of Chinese medicine, 2016, Volume: 44, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Animals; Drugs, Chinese Herbal; Extracellular S

2016
Cold-inducible RNA-binding protein mediates airway inflammation and mucus hypersecretion through a post-transcriptional regulatory mechanism under cold stress.
    The international journal of biochemistry & cell biology, 2016, Volume: 78

    Topics: 3' Untranslated Regions; Aged; Animals; Bronchitis; Cold-Shock Response; Cytokines; Female; Gene Exp

2016
Asiatic acid inhibits pulmonary inflammation induced by cigarette smoke.
    International immunopharmacology, 2016, Volume: 39

    Topics: Animals; Cell Movement; Centella; Cytokines; Drugs, Chinese Herbal; Heme Oxygenase-1; Humans; Inflam

2016
Therapeutic Effects of Resveratrol in a Mouse Model of LPS and Cigarette Smoke-Induced COPD.
    Inflammation, 2016, Volume: 39, Issue:6

    Topics: Animals; Beclin-1; Bronchoalveolar Lavage Fluid; Cytokines; Lipopolysaccharides; Lung; Mice; Mucus;

2016
NPS2143 Inhibits MUC5AC and Proinflammatory Mediators in Cigarette Smoke Extract (CSE)-Stimulated Human Airway Epithelial Cells.
    Inflammation, 2017, Volume: 40, Issue:1

    Topics: Active Transport, Cell Nucleus; Cell Line; Cytokines; Epithelial Cells; Humans; Inflammation Mediato

2017
Unusual Mucus Impaction in an Adolescent Patient With Severe Asthma.
    Clinical pediatrics, 2017, Volume: 56, Issue:14

    Topics: Adolescent; Asthma; Bronchoscopy; Glucocorticoids; Humans; Lung; Male; Mucus; Nitric Oxide; Pulmonar

2017
[State of the mucociliary system in patients of senior age with chronic obstructive pulmonary diseases].
    Advances in gerontology = Uspekhi gerontologii, 2008, Volume: 21, Issue:1

    Topics: Aged; Aging; Antioxidants; Female; Humans; Lipid Peroxidation; Male; Middle Aged; Mucociliary Cleara

2008
Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
    European journal of pharmacology, 2008, Oct-31, Volume: 596, Issue:1-3

    Topics: Administration, Oral; Animals; Asthma; Bronchoconstriction; Capillary Permeability; Capsaicin; Cough

2008
LPS-stimulated MUC5AC production involves Rac1-dependent MMP-9 secretion and activation in NCI-H292 cells.
    Biochemical and biophysical research communications, 2009, Aug-14, Volume: 386, Issue:1

    Topics: Cell Line, Tumor; ErbB Receptors; Humans; Lipopolysaccharides; Matrix Metalloproteinase 9; Mucin 5AC

2009
Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis.
    Pediatric pulmonology, 2009, Volume: 44, Issue:9

    Topics: Acetylcysteine; Administration, Inhalation; Bronchitis; Child, Preschool; Cystic Fibrosis; Expectora

2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 332, Issue:3

    Topics: Animals; Benzylamines; Cell Line; Cell Movement; Female; Guinea Pigs; Humans; In Vitro Techniques; I

2010
Mechanisms of clearance of nontypeable Haemophilus influenzae from cigarette smoke-exposed mouse lungs.
    The European respiratory journal, 2010, Volume: 36, Issue:5

    Topics: Animals; Antibodies, Bacterial; B-Lymphocytes; Bronchoalveolar Lavage Fluid; Female; Goblet Cells; H

2010
Chronic mucus hypersecretion: prevalence and risk factors in younger individuals.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2010, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Age Factors; Asthma; Child; Denmark; Diseases in Twins; Female; Humans; Male; Muc

2010
The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke.
    Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:7

    Topics: Animals; Bacterial Adhesion; Bacterial Load; Carbocysteine; Expectorants; Goblet Cells; Haemophilus

2010
Mucus hypersecretion in COPD: should we only rely on symptoms?
    European respiratory review : an official journal of the European Respiratory Society, 2010, Volume: 19, Issue:116

    Topics: Airway Obstruction; Cough; Humans; Mucus; Pulmonary Disease, Chronic Obstructive

2010
High-frequency and low-frequency chest compression: effects on lung water secretion, mucus transport, heart rate, and blood pressure using a trapezoidal source pressure waveform.
    IEEE transactions on bio-medical engineering, 2012, Volume: 59, Issue:1

    Topics: Biological Transport, Active; Blood Pressure; Body Water; Chest Wall Oscillation; Computer Simulatio

2012
STAT6 links IL-4/IL-13 stimulation with pendrin expression in asthma and chronic obstructive pulmonary disease.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:3

    Topics: Asthma; Base Pairing; Binding Sites; Cell Line; Epithelial Cells; Gene Expression Regulation; Humans

2011
Elastase/LPS-exposed mice exhibit impaired innate immune responses to bacterial challenge: role of scavenger receptor A.
    The American journal of pathology, 2012, Volume: 180, Issue:1

    Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Haemophilus Infections; Haemophilus inf

2012
Correlation and discriminant analysis between clinical, endoscopic, thoracic X-ray and bronchoalveolar lavage fluid cytology scores, for staging horses with recurrent airway obstruction (RAO).
    Research in veterinary science, 2012, Volume: 93, Issue:2

    Topics: Airway Obstruction; Animals; Cough; Horse Diseases; Horses; Mucus; Pulmonary Disease, Chronic Obstru

2012
Effect of Myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary disease.
    Arzneimittel-Forschung, 2011, Volume: 61, Issue:12

    Topics: Animals; Bronchodilator Agents; Cytokines; Drug Combinations; Expectorants; Immunohistochemistry; In

2011
[Effects of secretary leukocyte protease inhibitor-transfected bone marrow mesenchymal stem cells on airway inflammation and mucus secretion in chronic obstructive pulmonary disease].
    Zhonghua yi xue za zhi, 2011, Dec-27, Volume: 91, Issue:48

    Topics: Animals; Bone Marrow Cells; Male; Mesenchymal Stem Cells; Mucus; Pulmonary Disease, Chronic Obstruct

2011
Increased human Ca²⁺-activated Cl⁻ channel 1 expression and mucus overproduction in airway epithelia of smokers and chronic obstructive pulmonary disease patients.
    Respiratory research, 2012, Jun-25, Volume: 13

    Topics: Adult; Aged; Case-Control Studies; Chloride Channels; Epithelial Cells; Female; Forced Expiratory Vo

2012
Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: to establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease.
    Pulmonary pharmacology & therapeutics, 2012, Volume: 25, Issue:5

    Topics: Animals; Bronchi; Disease Models, Animal; ErbB Receptors; Histone Deacetylase 2; Lipopolysaccharides

2012
Docking protein Gab2 regulates mucin expression and goblet cell hyperplasia through TYK2/STAT6 pathway.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012, Volume: 26, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Animals; Epithelial Cells; Gene Expression Regulation; Goblet

2012
IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:12

    Topics: Binding Sites; Cells, Cultured; Chloride Channels; Crystallography, X-Ray; Drug Design; Epithelial C

2012
[The cutting-edge of medicine; Management and therapy for airway mucus hypersecretion].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2012, Dec-10, Volume: 101, Issue:12

    Topics: Asthma; Bronchiolitis Obliterans; Cystic Fibrosis; Humans; Mucus; Pulmonary Disease, Chronic Obstruc

2012
Mucus hypersecretion in respiratory disease. Chair's introduction.
    Novartis Foundation symposium, 2002, Volume: 248

    Topics: Animals; Asthma; Chloride Channels; Exocytosis; Humans; Inflammation; Lymphokines; Mice; Mucus; Pulm

2002
Chronic diesel exhaust exposures of rats demonstrate concentration and time-dependent effects on pulmonary inflammation.
    Inhalation toxicology, 2003, Apr-25, Volume: 15, Issue:5

    Topics: Animals; Bronchoalveolar Lavage Fluid; Dinoprostone; Inflammation; Lung; Male; Mucus; Pulmonary Dise

2003
Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland.
    American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 2004, Volume: 4, Issue:1

    Topics: Asthma; Base Sequence; Case-Control Studies; Chronic Disease; DNA Primers; Humans; Iceland; Mucus; P

2004
Scintigraphic measurement of tracheal mucus velocity in vivo.
    The European respiratory journal, 2004, Volume: 23, Issue:4

    Topics: Adult; Age Factors; Aged; Analysis of Variance; Gamma Cameras; Humans; Image Processing, Computer-As

2004
Effects of salmeterol on cilia and mucus in COPD and pneumonia patients.
    Pharmacological research, 2005, Volume: 51, Issue:2

    Topics: Albuterol; Cilia; Community-Acquired Infections; Female; Humans; Male; Mucus; Pneumonia; Pulmonary D

2005
[A comprehensive examination of the tracheobronchial contents in a gerontological practice].
    Klinicheskaia laboratornaia diagnostika, 2005, Issue:12

    Topics: Aged; Aged, 80 and over; Bronchi; Female; Humans; Leukocyte Count; Male; Mucus; Myocardial Ischemia;

2005
Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm.
    American journal of respiratory and critical care medicine, 2007, Jan-01, Volume: 175, Issue:1

    Topics: Adult; Chronic Disease; Cohort Studies; Cough; Dyspnea; Female; Humans; Incidence; Male; Mucus; Pulm

2007
Role of the airway epithelium in defense against inhaled invaders.
    COPD, 2005, Volume: 2, Issue:3

    Topics: Air Pollutants; Allergens; Animals; Epidermal Growth Factor; Epithelium; ErbB Receptors; Expectorant

2005
Chronic cough and phlegm in young adults: should we worry?
    American journal of respiratory and critical care medicine, 2007, Jan-01, Volume: 175, Issue:1

    Topics: Adult; Chronic Disease; Cough; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Risk

2007
[Potential therapy for mucus hypersecretion in chronic obstructive pulmonary disease].
    Zhonghua yi xue za zhi, 2006, Nov-07, Volume: 86, Issue:41

    Topics: Humans; Mucins; Mucus; Pulmonary Disease, Chronic Obstructive; Respiratory System

2006
Plasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary disease.
    American journal of respiratory and critical care medicine, 2007, Jun-01, Volume: 175, Issue:11

    Topics: Aged; Aged, 80 and over; Biomarkers; Bronchi; Bronchitis, Chronic; Disease Progression; Fluorescent

2007
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology.
    American journal of respiratory and critical care medicine, 2007, Sep-01, Volume: 176, Issue:5

    Topics: Adrenal Cortex Hormones; Cross-Sectional Studies; Disease Progression; Female; Forced Expiratory Vol

2007
Increased expression of human calcium-activated chloride channel 1 is correlated with mucus overproduction in the airways of Chinese patients with chronic obstructive pulmonary disease.
    Chinese medical journal, 2007, Jun-20, Volume: 120, Issue:12

    Topics: Adult; Aged; Bronchi; Chloride Channels; Female; Forced Expiratory Volume; Gene Expression Regulatio

2007
Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease.
    Acta pharmacologica Sinica, 2007, Volume: 28, Issue:8

    Topics: Aquaporin 5; Bronchi; Forced Expiratory Volume; Humans; Immunohistochemistry; Mucin 5AC; Mucins; Muc

2007
Increased expression of human calcium-activated chloride channel 1 gene is correlated with mucus overproduction in Chinese asthmatic airway.
    Cell biology international, 2007, Volume: 31, Issue:11

    Topics: Aged; Asthma; Calcium; China; Chloride Channels; Female; Gene Expression; Humans; Male; Middle Aged;

2007
Airway inflammation in COPD: friend or foe?
    American journal of respiratory and critical care medicine, 2007, Sep-01, Volume: 176, Issue:5

    Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Immunity; Inflammation; Mucus; Pulmonary Dise

2007
[The role of tumor necrosis factors (TNF-alpha) in patients with chronic obstructive lung disease in combination with stomach and duodenum ulcer diseases].
    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2007, Issue:4

    Topics: Helicobacter Infections; Helicobacter pylori; Humans; Mucus; Peptic Ulcer; Pulmonary Disease, Chroni

2007
Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease.
    Journal of immunology (Baltimore, Md. : 1950), 2008, May-01, Volume: 180, Issue:9

    Topics: Aged; Animals; Asthma; Chlorocebus aethiops; COS Cells; Disease Models, Animal; Epithelial Cells; Fe

2008
Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(+) cells.
    American journal of respiratory and critical care medicine, 2001, Dec-15, Volume: 164, Issue:12

    Topics: Aged; Aged, 80 and over; Bronchi; Bronchitis, Chronic; CD8-Positive T-Lymphocytes; Epithelium; Exocr

2001
Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B.
    The Biochemical journal, 2002, Feb-01, Volume: 361, Issue:Pt 3

    Topics: Asthma; Blotting, Western; Cystic Fibrosis; Dose-Response Relationship, Drug; Electrophoresis, Agar

2002
Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats.
    Biochemical and biophysical research communications, 2002, Mar-22, Volume: 292, Issue:1

    Topics: Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Budesonide; Eosi

2002
Cough and phlegm are important predictors of health status in smokers without COPD.
    Chest, 2002, Volume: 121, Issue:5

    Topics: Aged; Cough; Exercise Tolerance; Female; Forced Expiratory Volume; Health Status; Humans; Male; Maxi

2002
Does mucus hypersecretion matter in airway disease?
    Lancet (London, England), 2002, Jun-01, Volume: 359, Issue:9321

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Female; Humans; Male; Mice; Mucus; Niflumi

2002
Noninvasive detection of endotoxin-induced mucus hypersecretion in rat lung by MRI.
    American journal of physiology. Lung cellular and molecular physiology, 2002, Volume: 283, Issue:1

    Topics: Animals; Bronchoalveolar Lavage Fluid; Goblet Cells; Lipopolysaccharides; Magnetic Resonance Imaging

2002